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Chronic pain is a leading public health problem in the United States (US), affecting up to 
100 million people at a potential cost of $635 billion USD annually. In 2011, the Institute of 
Medicine released a report including a call to action for public agencies to study the impact and 
epidemiology of chronic pain in America.  In the 7 years since this call to action, there have only 
been a few studies estimating the national prevalence of chronic pain. Results from this body of 
work are challenging to assimilate due to the heterogeneity of methods used––including patient 
reported pain scores, patterns of diagnosis, and surveys. Furthermore, there are no national 
studies estimating trends in the prevalence of chronic pain in recent years. Chronic pain is 
particularly relevant to the Veterans Health Administration (VHA), as US Veterans are more 
likely to report chronic pain compared with their civilian counterparts.  
In the first aim of this work, we estimated temporal trends in the prevalence of chronic 
pain among all Veterans receiving primary care at the VHA between 2008 and 2015 
(n=7,821,152). Findings from this work demonstrate chronic pain (and related mental health 
comorbidities) are prevalent and increased in prevalence during the study period. These findings 
were robust to using pain scores or patterns of diagnoses to identify chronic pain. Conversely, 
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traditional chronic illnesses such as diabetes and cardiac disease were generally stable or 
decreasing in prevalence. In the second aim of this work, we proposed and evaluated a novel 
method for constructing an instrumental variable (facility prescribing preference for long term 
opioid therapy) using regularized general linear regression models in the context of repeated 
measures within facilities and over time. In the third aim of this work, we sought to identify the 
causal effect of exposure to long term opioid therapy on subsequent emergency department 
utilization. We contrasted approaches to control confounding including direct regression 
adjustment, propensity scores, and an instrumental variable analysis using the method developed 
in aim 2. Results from this work indicated that exposure to long term opioid therapy was a 
significant risk factor of moderate magnitude for subsequent emergency department utilization. 
The form and content of this abstract are approved. I recommend its publication. 
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              INTRODUCTION 
Background 
Chronic pain is a leading public health issue in the United States (US), affecting up to 
100 million people at a potential annual cost of $635 billion USD1. Chronic pain is unevenly 
distributed across demographics. Chronic pain rates are disproportionately higher among 
females, non-whites, and older patients2–4. Veterans are at a higher risk to experience chronic 
pain compared with their civilian counterparts4. Despite these well-documented disparities in 
chronic pain prevalence, estimates of the rate of chronic pain have varied substantially, from 
10% -40%2,5. This variation in rates is partially due to the large variation in the approaches used 
to identify chronic pain. These approaches include representative survey samples directly asking 
about the impact and duration of pain, as well analyses of electronic medical records of defined 
populations. Among studies leveraging electronic health records, diagnosis codes, pain scores, 
and opioid prescriptions have all been used to identify patients reporting chronic pain. 
Considering the heterogeneity in methods and the subsequent results, assimilating this body of 
knowledge is challenging.  
In 2011, the Institute of Medicine released a report including a call to action for public 
agencies to study the impact and epidemiology of chronic pain in America.  In the 7 years since 
this call to action, there have only been a few studies of the national prevalence of chronic pain 2–
4,6,7. As the largest integrated healthcare system in the United States, serving 6 million unique 
Veterans per year, the Veterans Health Administration (VHA) is uniquely positioned to analyze 
the prevalence of conditions related to chronic pain in the context of other prevalent chronic 
diseases. The VHA has a robust, national electronic health record (EHR). In addition to 
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documenting encounters by assigning diagnostic codes, the VHA routinely collects pain scores 
for Veterans in outpatient and inpatient encounters. To our knowledge, there has been no prior 
study of chronic pain leveraging a longitudinal, national US cohort that could identify changes in 
the prevalence of chronic pain over time. Furthermore, any observed changes in the prevalence 
of chronic pain over time may be due to demographic changes in the underlying patient 
population. There is a need to identify longitudinal trends in the prevalence of chronic pain and 
other common chronic conditions in a large healthcare system, while considering the context of 
changing demographics on these trends.  
In addition to potential changes in the prevalence of chronic pain and demographics of 
Veterans in recent years, there have been substantial changes in the national VHA prescription 
rates of long term opioid therapy (LTOT). The VHA implemented the Opioid Safety Initiative 
(OSI) in 2011. Between 2010 and 2016, the prevalence of opioid prescribing in the VHA fell 
from 20.8% to 16.1%8.  However, it is unknown what effect these reductions in LTOT have had 
on Veterans’ health outcomes---particularly Veterans reporting chronic pain.   
This change in health policy resulting in substantial changes in practice is a unique 
opportunity to study the effect of LTOT on health outcomes. A recent clinical trial found opioid 
assisted therapy was not associated with a difference in pain-related function9.  Prior 
observational studies have shown LTOT is associated with increased emergency department 
visits and alcohol or drug related adverse events10. Unfortunately, establishing causal 
relationships using observational data is fraught with potential sources of bias. Patients who are 
exposed to a given therapy, such as LTOT, are often systematically different from patients who 
are not exposed. For example, prior studies have found mental health diagnoses and level of pain 
are associated with exposure to LTOT11. If these differences are not fully captured by observed 
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covariates, any observed association may be biased due to unobserved confounding. This is 
called treatment indication bias. If all confounders are observed, methods such as direct 
regression adjustment or propensity score matching can give an unbiased estimate of the average 
treatment effect (ATE) associated with exposure. In the presence of unobserved confounders, 
these methods will give biased results, and approaches robust to unobserved confounding are 
required.  
One method robust to unobserved confounding is instrumental variable analysis. 
Instrumental variable analysis is a method that seeks to identify a variable that is correlated with 
treatment, but uncorrelated with the outcome (except through treatment). One possible 
instrument in the context of LTOT is provider-prescribing preference. If there is substantial 
variation in LTOT exposure attributable to providers (or facilities), identifying high and low 
prescribers of the therapy may be a valid instrument to use to overcome unobserved 
confounding. However, the instrument is unobserved and must be estimated from the data. There 
is a robust set of literature on the identification of outlier facilities with respect to hospital 
profiling, including random effects models, empirical shrinkage estimators, and Bayesian 
approaches. Although there is no consensus on a single best approach, there is agreement that 
some form of shrinkage is required to reduce sensitivity to statistical noise, and conditioning on 
patient traits is required to adjust for patient mix. Despite this, prior studies implementing a 
provider preference instrumental variable analysis have not used advanced statistical methods to 
identify the instrument. In the context of patients unevenly distributed amongst facilities with 





Using a national cohort of Veterans regularly engaged in primary care at VHA facilities, 
the overall aim of this research is to describe trends in the prevalence of chronic pain amongst 
Veterans between 2008-2015 and describe the association between long term opioid therapy and 
subsequent emergency department utilization among Veterans reporting incident chronic pain. 
To inform an instrumental variable analysis of LTOT and ED utilization, an intermediate aim of 
this work is to contrast different approaches to identifying facility prescribing preference using 
longitudinal prescribing data.  
• Aim 1: To identify temporal trends in the prevalence of chronic pain among Veterans 
receiving care at the VHA and determine whether these trends are explained by changes 
in Veteran demographics.  
o Hypothesis: The prevalence of chronic pain among Veterans has increased in the 
past 10 years. Consistent with other studies, non-white and female Veterans are at 
a higher risk of chronic pain. The increasing prevalence of chronic pain is not 
explained by changes in Veteran demographics.  
• Aim 2: To implement traditional approaches to site-prescribing preference identification 
using no shrinkage and no case-mix adjustment, as well as observed over expected ratios 
using multiple prior time points and different degrees of shrinkage via an elastic net 
penalized Poisson general linear model.  
o Hypothesis: The optimal approach to identifying time-varying facility prescribing 
preference will require a moderate amount of shrinkage, and data covering 
multiple prior year-quarters.  
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• Aim 3: To identify the association between LTOT and subsequent one-year ED 
utilization using different approaches including a general linear model with direct 
regression adjustment, a propensity score model using inverse probability of treatment 
weights, and an instrumental variable analysis using facility prescribing preference as an 
instrument.  
Hypothesis: Exposure to LTOT will be associated with a higher probability of ED 
utilization in the following year using all three approaches. Propensity score matching will 




           LITERATURE REVIEW 
Chronic Pain 
Pain is a prevalent and disabling condition that is estimated to cost US$365 billion per 
year1. Defining the impact of pain requires a specific definition for pain as a condition, but the 
experience of pain is inherently subjective12,13. Whether pain should be viewed as an underlying 
condition, or as a symptom of other conditions has been debated in the literature14–16. Perhaps the 
difference in these perspectives can be reconciled by considering acute versus chronic pain. The 
International Association for the Study of Pain (IASP) defines chronic pain as pain lasting 
beyond the normal healing period for a given injury, or as persistent pain lasting longer than 
three months17. A shortcoming of linking chronic pain directly to tissue injury healing is the lack 
of recognition of the experience of persistent pain without underlying injury. Chronic pain has 
further been described based on functional limitations associated with underlying persistent pain. 
As early as 1990, Korff argued that chronic pain should be described across the dimensions of 
recurrence, persistence, and disability18. Recently, it has been argued that understanding chronic 
pain requires the recognition of multiple overlapping pain conditions19. Although there is not 
agreement on a definition of chronic pain across the sources listed above, there is agreement that 
chronic pain cannot be viewed only through the lens of underlying pathologic injury.  
Although it is challenging to identify a single definition for chronic pain, studying 
chronic pain at a population level requires a case definition. Reports of the prevalence of chronic 
pain have been inconsistent, ranging from under 10% to over 50%5,5. The heterogeneity in 
methods used to identify chronic pain certainly contribute to the variance in these estimates; 
however, specific methods have not been consistently associated with higher or lower estimates. 
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Reports of the prevalence of chronic pain have primarily relied on survey sampling and 
secondary analysis of clinical data. Using the 2012 National Health Interview Survey, Nahin 
estimated that 55% of US adults experienced pain in the prior 3 months, but only 11.2% reported 
chronic pain in the three months prior to the survey4. An internet-based study using a nationally 
representative sample of US adults identified chronic pain prevalence to be 30.7%20.  A 
longitudinal study from Canada estimated the prevalence of chronic pain in Canada to be 
between 15-20% from 1994 to 200721. In a survey including both developing and developed 
countries, the prevalence of chronic pain (based on underlying common conditions) was 37% in 
developing countries and 41 in developed countries22.  A study from Hong Kong estimated the 
chronic pain prevalence among Hong Kong residents to be 35%23. A chart review of 300 
randomly sampled US Veterans from 2002 found that 50% of patients experienced one or more 
chronic pain conditions24.  Several studies have reviewed data collected for clinical purposes to 
estimate the prevalence of chronic pain. Lamerato et al found that 12% of adult patients in a 
vertically integrated healthcare system were diagnosed with an underlying chronic pain 
condition, where musculoskeletal conditions were the most common2. Tian et al used an 
approach integrating diagnoses likely to be related to chronic pain, persistently elevated pain 
scores, and exposure to long term opioid therapy to identify chronic pain. Using this algorithm, 
they found 19.4% of patients to be reporting chronic pain in a regional US health center in the 
state of Connecticut25.  
Data on trends in the prevalence or incidence of chronic pain in specific populations is 
less common, as longitudinal follow-up or multiple cross-sectional studies from the same 
population are required. A study from Sweden26 found a slight increase in the prevalence of 
neck-shoulder-arm pain between 1990 and 2006. In Canada, a longitudinal survey study found 
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the prevalence of chronic pain was also modestly increasing between 1996 and 200721. Condition 
specific estimates of trends in pain have been more commonly published. For example, 
integrating data from multiple studies, Manchikanti et al found that low back pain is generally 
increasing in prevalence27.  
The consequences of uncontrolled chronic pain are severe. Negative outcomes include 
higher risks of depression, increases risk of suicide, and poor quality of life. The second leading 
medical cause of depression is chronic pain28,29. Among patients experiencing neuropathic pain, 
the impact of chronic pain on quality of life is larger than renal failure, depression, or heart 
failure30. Recent qualitative work reported providers believe patients who experience 
uncontrolled chronic pain frequently use the emergency department to seek care and relief. 
Quantitative analyses in that health system backed up this perspective; Patients with conditions 
likely related to chronic pain were 2-3 times more likely to use the emergency department31.  
Although the physiologic mechanisms are not well described, one study found an 
increased risk of mortality over 10-years among patients with poorly controlled chronic pain. 
The risk was substantially higher than the risk from other chronic conditions32, and this increased 
risk was not explained by socio-demographic factors. 
Identifying Chronic Pain from Administrative Data 
The focus of the first aim of this dissertation is to estimate the prevalence of chronic pain 
using electronic health records data routinely collected for clinical care. The studies mentioned 
above have used various approaches to identifying chronic pain from administrative data, 
including diagnosis codes associated with visits, 11-point numeric rating scale scores, exposure 
to medications used to treat pain (such as opioids), exposure to non-pharmacologic treatments for 
pain, and utilization of pain specialty care. To our knowledge, only a single study has contrasted 
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the accuracy of these different approaches and tested a combined algorithm against the gold 
standard of chart review. Tian et al considered use of persistently elevated pain scores, diagnoses 
of conditions likely related to chronic pain, and exposure to opioid therapy25. They concluded 
that an algorithm combining all three elements optimized sensitivity and specificity. Other 
studies have implemented combinations of these signals to identify chronic pain7, including a 
study examining the costs of chronic pain among patients COPD defined chronic pain based on 
diagnoses, exposure to pain medication, or procedure based pain therapy33–36. To our knowledge, 
there is no consensus in the literature on the optimal method for defining chronic pain using 
administrative data.  
Numeric Pain Scale 
The 11-point pain numeric scale (NRS) is a tool used to identify self-reported pain. No 
pain is considered a score of 0, while mild pain is 1-3, moderate pain is 4-6, and severe pain is 7-
10. The accuracy of NRS scores administered by clinical personal in regular practice has been 
questioned. Lorenz 2009 found37 only moderate correlation between nurse administered NRS 
scores, and research administered NRS scores. However, there was a high degree of correlation 
between the research administered NRS scores and pain interference measures, indicating the 
NRS score is a good surrogate for pain interference, if administered properly. Two points on the 
NRS has been identified as a minimally clinically meaningful change in multiple studies38–41. 
Using a cohort of Veterans, Dobsha et al 201542 identified moderate variation in pain scores 
within a given month that corresponded to clinically meaningful cut points. Their work 
underscores the importance of considering multiple pain scores over time when defining chronic 
pain.  Despite the potential issues highlighted above, many prior studies have used this data and 
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cut offs to study ‘persistently elevated pain scores’ by identifying persistently elevated pain 
scores over a given time period7,25,35,36,43,44.  
Conditions Related to Chronic Pain 
Another approach to identifying chronic pain is to identify the presence of underlying 
patient conditions that are often associated with chronic pain. Common chronic conditions 
associated with chronic pain include musculoskeletal conditions, abdominal pain, neuropathic 
conditions, cancer, and obstructive pulmonary disease2. Some prior work has been condition 
specific, viewing pain as a symptom of the underlying condition. Examples include registries of 
musculoskeletal conditions6, COPD33, low back pain diagnoses45, and neuropathic pain46–49. 
Other work has broadened the case definition of chronic pain to include multiple possible 
underlying causes, but still required a diagnosis of an underlying condition to define chronic 
pain2. 
Combining Diagnosis Codes and Pain Scores 
Using only diagnosis codes may miss some patients who are experiencing chronic pain 
without a clear link to an underlying condition, or chronic pain comorbid with a chronic illness 
that is not strongly associated with chronic pain. For this reason, we believe the optimal 
approach to identifying chronic pain includes using both patient reported pain measures (such as 
the NRS) and diagnoses of chronic conditions related to chronic pain. Some other studies have 
additionally included chronic exposure to pain specific medications (often opioids) as part of the 
case definition for chronic pain7,25,36. The clinical reasoning is sound, since the only indication 
for long term opioid therapy is chronic pain.  
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Challenges in Using EHR Data to Identify Chronic Pain 
Estimating the prevalence of chronic pain in a large population is inherently challenging. 
The optimal data collection strategy would include assessing the severity, persistence, regularity, 
and impact of pain for each individual in a longitudinal fashion50. However, this data is not 
routinely collected in clinical care and thus the cost of collecting this data in a large population is 
prohibitive. Diagnoses, medication and treatment exposures, and NRS scores are routinely 
collected in clinical care across populations, and are often used to identify chronic pain. But 
these measurements are inherently dependent upon utilization. Requiring multiple elevated pain 
scores or diagnoses for conditions increases the specificity of the construct, but may miss 
patients who lack the opportunity to report pain scores or diagnoses due to low utilization.  
Disparities in Chronic Pain 
Prior studies have consistently found non-white race, female gender, and older age are 
associated with an increased prevalence of chronic pain2,4,5,20,23,51. Nahin (2015) found that 
female, older, and non-Hispanics were more likely to report pain. In both developed and 
developing countries, female and older age were associated with increased prevalence of chronic 
pain22. An internet based survey found the older age and female gender were associated with an 
increased prevalence of chronic pain20. A survey of Hong Kong residents found female and older 
age were associated with an increased prevalence of chronic pain23. Other studies examining pain 
frequency and severity are less conclusive52.  In contrasting work, Burgess found no association 
between race and pain interference, or between race and the perceived effectiveness of pain 
treatments53  using a national survey of Veterans receiving care at the VHA.  
Veterans are a unique subset of the US population. Veterans as a group are more likely to 
report chronic pain4, and have high rates of diagnoses of pain-related conditions54,55. The 
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association between demographics and the prevalence of chronic pain may differ in Veteran 
versus non-Veteran populations.  A recent study by Nahin comparing Veterans to non-Veterans 
on the same survey dataset found a non-linear relationship between pain prevalence and age 
among US Veterans; Veterans in the oldest age group were less likely to report chronic pain than 
Veterans in the middle age groups. This is in contrast to the findings from non-Veterans using 
the same survey dataset4.  Another study of gender and pain scores among a small sample of 
electronic medical records of US Veterans found no association between gender and pain scores 
among Veterans of the Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) 
wars56. Another study of OEF/OIF Veterans found the female Veterans were equally likely to 
receive a pain assessment, slightly less likely to report any pain, and slightly less likely to report 
persistent pain. This is contrast to the findings of civilian population across multiple countries 
presented above. Considering the number of female is substantially increasing57, understanding 
Veteran specific gender disparities in the experience of chronic pain is critical.  
Opioid and Non-Opioid Treatments for Chronic Pain 
Guidelines for treating patients reporting pain have evolved substantially over the past 
two decades58–61. In the 1995, a consensus statement from the American Pain Society focused on 
the issue of underdiagnosed and undertreated pain conditions. By 2005, the revised consensus 
statement defined ‘high quality pain management’ as interdisciplinary and collaborative across 
multiple providers as well as patients and family. The statement also called for a reduction of the 
use of non-evidence based treatments, specifically intramuscular injections and ‘as-needed’ 
analgesic medication treatment plans. The statement calls for multi-modal treatment, without 
excluding opioid therapy as an aspect of that treatment.  In 2008, another set of 
recommendations was released by the American Pain Society for the safe prescribing of opioids 
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in the context of chronic pain62. In the context of steadily increasing opioid prescriptions in the 
2000’s, the focus of the recommendations was on how to appropriately and safely use opioid 
therapy in the context of chronic pain. There was no call for a global reduction in the use of 
opioids for chronic pain in this document; furthermore, they note there was a lack of evidence at 
the time to even support recommendations about using opioids in the context of chronic pain.  In 
2016, the Center for Disease Control (CDC) released recommendations for the use of opioid 
therapy in the context of chronic pain61. These recommendations note there is still poor quality 
evidence (at the time) to assess the effectiveness of opioid therapy. However, they state ‘non-
opioid therapy should be preferred to opioid therapy for the treatment of chronic pain’. 
Furthermore, ‘Opioids were associated with increased risks, including opioid use disorder, 
overdose, and death, with dose-dependent effects’. 
The efficacy of opioids for conditions related to chronic pain have been debated in the 
literature for at least the past 20 years24,63–65. Recent work has directly addressed the efficacy of 
opioids in patients reporting chronic pain. Burgess and colleagues linked opioid exposure data to 
national survey data among US Veterans receiving care at the VHA. Veterans exposed to opioids 
had a subsequently higher pain interference score, leading the authors to speculate if LTOT is 
effective for treating chronic pain53.  A systematic review in 2015 concluded there was 
insufficient evidence to assess the effectiveness of long-term opioid therapy at the time, with 
only a few low quality observational studies66. A subsequent clinical trial conducted by Krebs 
testing opioid assisted therapy versus nonopioid medications among Veterans reporting chronic 
back pain, knee or hip osteoarthritis found no difference in pain-related function, and a lower 
pain intensity score among those treated with opioids9. These findings support the hypothesis 
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that LTOT is not an effective treatment for chronic pain. However, there is not strong evidence 
that non-opioid alternatives are superior.  
The harms associated with long-term opioid therapy in a general population of patients 
experiencing chronic pain remain poorly defined. The same metanalysis66 from 2015 identified a 
few observational studies that found LTOT exposure was associated with an increased risk of 
diagnosis of opioid abuse, increased risk of any overdose, small increased risk of fractures, and 
increased risk of MI. There may be an association between sleep disorders and long-term opioid 
therapy—a small observational study of patients seen in a pain clinic found a dose-response 
relationship between sleep apnea and exposure to opioid therapy. An observational study of 
Medicaid beneficiaries in Tennessee found a small but statistically significant relationship 
between exposure to long acting opioid medication and mortality67.  
There was an increase in overall opioid prescribing throughout the 2000’s—
simultaneously, there was an increase in negative outcomes associated with opioids including 
addiction and overdose68,69. The public health crisis of opioid abuse and the opioid overdose 
epidemic are often associated with opioid analgesics prescribed to the general population70. 
However, the opioid overdose epidemic is primarily driven by illicit use of fentanyl and heroin, 
rather than more standard opioid analgesics. 
Opinions on the topic remain mixed. For example, Rose70 acknowledges that evidence of 
the effectiveness of LTOT for chronic pain is lacking, but that recent reviews by the CDC and 
the AHRQ ‘misleads with strongly biased wording and omitted information… Absence of 
evidence is not evidence of absence’. Given the heterogeneity of the current state of scientific 
opinion on the safety and efficacy of opioid therapy for chronic pain, further data points to 




          METHODS 
 
Study Subjects and Design 
In all aims of this work, we conducted a retrospective cohort study by using existing 
electronic health records to identify Veterans receiving care in the Veterans Health 
Administration (VHA). In aim 1, we sought to identify a cohort of Veterans actively receiving 
primary care in the VHA health system between 2008-01-01 and 2015-06-01. This cohort 
comprised the population ‘at-risk’ for reporting chronic pain during the year following baseline 
date. Baseline date is defined as the first date the Veteran was observed to be in active primary 
care (further described below). In aim 2, we identified a cohort of Veterans in active primary 
care and reporting incident chronic pain. In aim 3, we identified a cohort of Veterans in active 
primary care at VHA medical centers and reporting incident chronic pain.  
We discretized follow-up time into calendar year quarters in all aims of this work. 
Therefore, we generally describe time intervals in terms of number of calendar year quarters 
rather than number of days.  
VHA Data 
We used national electronic health records from the VHA for all aspects of this analysis. 
The VHA has a national electronic health record system. The VHA records clinical care data at 
the regional level, such as diagnosis codes, lab values and vital signs. The VHA also maintains a 
patient file with Veteran demographic data. The VHA maintains a vital status file, with date of 
death indicated for each deceased Veteran. This regional data goes through business rules to 
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assist with data accuracy, and is then aggregated to national servers as a single data source. This 
data source is referred to as the central data warehouse (CDW).  
Cohort Construction 
In aim 1, we identified a national cohort of Veterans in active primary care between 
2008-01-01 and 2015-06-01. We defined ‘active primary care’ as any primary care visit in the 
prior two years. Accordingly, we identified all Veterans with an outpatient primary care visit in 
the VHA between 2006-01-01 and 2015-06-01. Amongst those Veterans, we limited the cohort 
to Veterans with no recorded date of death prior to 2008-01-01. Outpatient visits were classified 
as primary care by clinic stop code using the VHA electronic healthcare record. The result of this 
algorithm identified Veterans with a record of primary care utilization no more than two years 
prior to the study start date of 2008-01-01. Veterans with missing values for gender, date of 
birth, race, or ethnicity were excluded from the study cohort. A small portion of Veterans were 
identified to have multiple values for race. These Veterans also had excessively higher observed 
utilization, leading to higher rates of all utilization-based variables and outcomes. Accordingly, 
these Veterans were excluded from the study, as the most likely explanation is data or Veteran 
identifier errors. 
In Aim 2, we limited this cohort further to Veterans reporting incident chronic pain as 
indicated by persistently elevated pain scores, or diagnoses of chronic conditions related to pain. 
The definition of chronic pain is further described below. We identified the first quarter in which 
a Veteran reported chronic pain, and considered the first day of this quarter to be the Veteran’s 
baseline date. If a Veteran reported chronic pain in any of the quarters between 2006 and 2008, 
they were considered prevalent cases and excluded from the study (a two-year washout period). 
Veterans were linked to their home primary care facility as described below. Veterans whose 
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home primary care facility was a medical center, outpatient clinic or health care center were 
included in the cohort for aim 2. 
In Aim 3, we limited this cohort further to Veterans reporting incident chronic pain who 
are actively engaged in primary care at VHA medical centers.   
Identifying Home Facility 
Each Veteran was assigned to a home facility based on patterns of primary care visits in 
the 4 quarters preceding baseline, and the quarter including baseline. We extracted all outpatient 
visits occurring in primary care clinics as indicated by clinic stop codes. We then aggregated 
these visits by facility identifier, and took the most frequently occurring facility as the ‘home 
facility’. Type and rurality of facility was used in the analysis. Facilities were classified as 
medical centers, urban community-based outpatient clinics, and rural community-based 
outpatient clinics. Urban/rural status of facilities is maintained by the VHA Planning Systems 
and Support Group.  
Identifying Veteran Comorbidity and Demographics  
We identified chronic comorbidities using international classification of disease (ICD) 
diagnostic codes, including congestive heart failure, uncomplicated diabetes, complicated 
diabetes, lymphoma, metastatic cancer, obesity, chronic pulmonary disease, peripheral vascular 
disorders, renal failure, solid tumor without metastasis, valvular disease, and liver disease. We 
also identified suicidal ideation, suicide attempt or self-injury, organic or non-organic sleep 
disorders, post-traumatic stress disorder, traumatic brain injury, concussion, depression, anxiety 
disorder, schizophrenia and other psychotic disorders, bipolar or manic disorder, opioid use 
disorder, alcohol related disorders, and other substance abuse disorder. ICD9/10 codes for these 
conditions were grouped using the Agency for Healthcare Research and Quality (AHRQ) 
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Clinical Classifications Software (CCS) combined with expert review of codes. Following prior 
VHA studies6, we required one inpatient or two outpatient diagnoses on separate days between 
the prior 4 quarters and the quarter after the baseline date.  
Veteran demographics including age, race, ethnicity, gender, and urban/rural status were 
identified from the VHA central data warehouse. Age was calculated as of the first day of each 
quarter, and categorized into groups of 18-35, 35-45, 45-55, 55-65, 65-75, and 75+. Race and 
ethnicity were categorized into a single variable as white non-Hispanic, black non-Hispanic, 
Hispanic, and other.  
Veteran demographics including age, race, ethnicity, gender, and urban/rural status were 
identified from the VHA central data warehouse. Age was calculated as of the first day of each 
quarter, and categorized into groups of 18-35, 35-45, 45-55, 55-65, 65-75, and 75+. Race and 
ethnicity were categorized into a single variable as white non-Hispanic, black non-Hispanic, 
Hispanic, and other. 
Identifying Chronic Pain 
We sought to define Veterans reporting chronic pain by Veteran reported pain scores, as 
well as patterns of diagnostic codes. Chronic pain is commonly defined as pain lasting longer 
than 3 months71. The VHA regularly captures pain scores during encounters using the numeric 
pain rating scale (REF), where 0 represents no pain, and 10 represents the worst possible pain. 
Following prior studies (REF), we defined pain scores of 1-3 as mild pain, pain scores of 4-6 as 
moderate pain, and pain scores of 7-10 as severe pain. To identify persistent pain, we identified 
Veterans reporting at least three pain scores of 4 or higher (moderate to severe pain), with at least 
30 days between the pain scores, but no more than 365 days between the first and last pain score. 
Veterans meeting this criterion were considered to reporting persistent moderate-severe pain. We 
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repeated this algorithm for pain scores of 7 or higher to identify Veterans reporting persistent 
severe pain. Veterans meeting these criteria were defined as reporting persistent pain as of the 
date of the first pain score.  
In addition to using pain scores to identify Veterans reporting chronic pain, we used 
diagnosis codes to identify Veterans with conditions likely to occur with chronic pain. 
Conditions were identified based on prior work2,25 and included joint pain, limb pain, back and 
neck pain, osteoarthritis and spondylosis, abdominal pain, headache and migraine, arthropathy, 
rheumatoid arthritis and inflammatory polyneuropathies, neuropathies, fibromyalgia, multiple 
sclerosis, painful bladder syndrome, genitourinary pain, multiple dystrophy, spinal cord injury, 
central pain syndrome, post-operative pain, and cancer pain. Veterans were required to have at 
least two diagnosis codes (inpatient or outpatient) with at least 90 days but no more than 365 
days between the diagnosis code dates. Veterans meeting this condition were defined as 
experiencing a chronic pain related condition as of the first diagnosis code.  
We next identified if a Veteran was reporting persistent moderate-severe pain, reporting 
persistent severe pain, or experiencing a pain related condition during each quarter at risk. If a 
Veteran had a valid pain date as described above in the current quarter or prior 4 quarters, they 
were considered reporting the pain condition of interest.  
Long Term Opioid Therapy 
Long term opioid therapy was defined as 90 or more days supply of opioids within any 
365 day period. The opioids included butorphanol, codeine, fentanyl, hydrocodone, 
hydromorphone, levorphanol, meperidine, morphine, oxycodone, oxymorphone, pentazocine, 
propoxyphene, tapentadol, or tramadol. A veteran was considered exposed to long term opioid 




In aim 3, the primary outcome of interest is any emergency department (ED) utilization 
in the second through fourth quarters following baseline for each Veteran. ED utilization was 
identified using VHA electronic medical records, based on clinical stop codes for emergency 
department and urgent care (clinic stop codes 130, 131, 297). 
Population Comparisons 
We compared the distribution of comorbidities and Veteran demographics in table 1 for 
all three aims. We summarized continuous variables with the mean and standard deviation, and 
categorical variables with the frequency and proportion. Considering the large number of 
Veterans in the dataset and the lack of individual hypotheses corresponding to pairwise 
comparisons amongst Veteran traits, we did not include p-values for the pairwise comparisons 
made in each table 1. Instead, we present standardized mean differences across the columns.  We 
use a cutoff of 0.1 to identify covariates with notable imbalances across these time points72. 
Period Prevalence Identification 
In the first aim of this work, we calculate the period prevalence of chronic pain for each 
calendar year quarter between 2008-01-01 and 2015-06-01. We identified an at-risk population 
during each calendar-year quarter as described above, then calculated the prevalence of chronic 
pain during the that calendar-year quarter. The period prevalence is defined as the proportion of 
an at-risk population that experienced the disease during a specific period. Since we discretized 
follow-up time into calendar year quarters, we then calculated the period prevalence for each 
calendar year quarter as the total number of Veteran reporting chronic pain divided by the total 
number at risk. 
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In Aim 1, we also sought to summarize the average change in the prevalence of chronic 
pain across time during the study period, adjusted for Veteran demographics (age category, race, 
gender). To estimate the prevalence ratio (risk ratio) of chronic pain associated with calendar 
time, we used a generalized linear model with a log link and a quasi-Poisson distribution. The 
dependent variable was chronic pain defined by pain scores or diagnoses. In the first model, we 
used continuous calendar time as the independent variable. In the second model, we used 
continuous calendar time, age, race and gender as independent variables.  
Observed Over Expected Ratios 
In the second aim of this work, we sought to estimate observed over expected ratios for 
each facility at each calendar year-quarter between 2009-01-01 and 2015-06-01. The numerator 
of this calculation is the observed number of Veterans exposed to LTOT for each facility-
calendar year combination. The denominator is the expected number of Veterans exposed to 
LTOT for each facility-calendar year combination. An OE ratio greater than 1 indicates the 
facility had a higher than expected exposure rate, while an OE less than 1 indicates the facility 
had a lower than expected exposure rate. We derived the expected number of Veterans by first 
calculating a probability of LTOT exposure for each Veteran as a function of Veteran traits 
(demographics and comorbidities) and then summing those exposure probabilities for each 
facility-calendar year combination. We varied the method for calculating the Veteran level 
exposure probability as described below.  
Calculating Veteran Level LTOT Exposure Probabilities 
In Aim 2, we considered several methods for calculating the sum E.  Accurately 
estimating the Veteran level probability of LTOT exposure conditional on Veteran traits requires 
correctly specifying an underlying model. Since the underlying model is unknown, we 
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considered different possible models. The four models included A) a null model for comparison 
purposes, where the predicted probability of LTOT was simply the average population exposure 
(no case mix adjustment), B) a logistic regression, C) an elastic-net regularized logistic 
regression73, and D) a random forest74. This resulted in 4 distinct methods for estimating the 
expected probability of Veteran-level LTOT exposure for use in the observed over expected 
ratios. We identify the choice method as ensemble parameter mod.  These methods are 
summarized in the top panel of Figure 2. 
Since we are interested in accurate prediction rather than inference, we used a machine 
learning approach to maximize the predictive ability of the four different models. We 
implemented 10-fold cross validation75 using area-under-the curve (AUC) calculations to 
optimize model hyperparameters as needed.  For the elastic net, we considered alpha values  of 
0, 0.25, 0.5, 0.75, and 1. For the random forest, we considered mtry values  of 2, 4, 6, and 10. 
Due to computing constraints, the initial hyperparameter search for the random forest model was 
developed on a random sample of 50,000 Veterans. After selecting mtry using that sample, we 
implemented the random forest on a random sample of 1,000,000 Veterans. 
Shrinkage Estimators 
Methods for stabilizing estimates in sparse data typically leverage information sharing 
from other closely related data points, where the degree of relatedness is inferred from the 
structure of the data. If there are repeated measurements on a single unit, prior measurements 
that are close in time may be correlated with the current measurement of the same unit. 
Similarly, if a unit is part of a cluster of other similar units (such as medical facilities), we may 
infer the unit is correlated with other units to some degree. If there are clusters of correlated 
observations as described, the accuracy of predictions of an individual cluster can be improved 
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by sharing information among clusters, or within a single cluster over time. Estimators that share 
information in this way are referred to as ‘shrinkage estimators’76, since the observed cluster 
average is being ‘shrunk’ towards the average of other data points. Estimators with this behavior 
have been proposed and implemented extensively using different frameworks and under different 
names, including random effects models77,78, Bayesian inference via priors79, regularized general 
linear models73,80, and empirical shrinkage estimators81.  
In aim 2, we estimated facility observed over expected ratios of LTOT exposure using 
data on observed and expected LTOT exposure in prior quarters. We implemented Poisson 
generalized linear models (GLM) with elastic-net regularization73 , where the degree of 
shrinkage can be specified as lambda, and the shape of the shrinkage can be specified as alpha. 
We sought to describe the impact of varying the degree of shrinkage both within facility across 
time, and between facilities for a single point in time. 
To estimate the observed over expected ratios for each facility in each year quarter, we 
used separate Poisson generalized linear models with elastic-net regularization 73 for each year 
quarter. The dependent variable was the observed number of Veterans exposed to LTOT in the 
prior year-quarter (s), and an offset of the log of the expected number of Veterans exposed to 
LTOT in the prior year quarter(s) was added to the model. The expected number of Veterans 
exposed to LTOT in each prior year-quarter was calculated as the sum of the individual 
Veterans’ expected probabilities of LTOT for each facility. Since there were four different 
methods implemented to estimate the Veteran level probability of LTOT exposure, this modeling 
process was repeated four times, once for each of those methods. For each year-quarter between 
2009-01-01 (2009Q1) and 2015-06-01 (2015Q2), we repeated this approach using 1, 2, 3, or 4 
prior quarters of data to estimate the observed over expected ratio for each facility. When only 
24 
 
one prior quarter was used, the elastic-net regularized Poisson GLM included home facility as an 
independent categorical predictor coded with a referent group. This is conceptually parallel to a 
random intercept under a generalized linear modeling approach. When more than one prior 
quarter was used, the elastic-net regularized Poisson GLM included facility, time, and a facility 
by time interaction term. In this model, the time parameter was not subjected to regularization, 
but the facility and time by facility interaction terms were subjected to regularization. This is 
conceptually similar to including a random intercept and random slope under a generalized linear 
modeling approach.  
The appropriate degree (strength) of shrinkage for the time varying facility observed over 
expected estimates is unknown. Since we used an elastic net regularization, the degree and shape 
of shrinkage can be controlled via the alpha and lambda parameters used in the regularizing 
function. Alpha includes values between 0 and 1, with 0 corresponding to a LASSO regression 
and 1 corresponding to a ridge regression. Lambda includes values of 0 or greater, with 0 
indicating no shrinkage, and increasing values of lambda indicating stronger shrinkage. In this 
ensemble, we considered values of 0, 0.25, 0.5, 0.75, and 1 for alpha and values of 0.001, 0.01, 
0.1, 0.5, 1, 5, 10, 50, 250, and 500 for lambda. 
Propensity Score Analysis 
In aim 3, we implemented a propensity score analysis to estimate the average treatment 
effect (ATE) of LTOT and any emergency department utilization. We used propensity score 
analysis with inverse probability of treatment weighting to adjust for measured confounders82,83.  
We first estimated the probability of LTOT exposure using a logistic regression with Veteran 
demographics, chronic comorbidities, and chronic pain conditions as independent variables. We 
examined the distribution of the LTOT probabilities stratified by LTOT status to check for valid 
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counterfactuals. We then weighted each observation per the inverse probability of treatment and 
implemented a logistic regression with LTOT as the single independent variable, and ED 
utilization as the dependent variable. The primary analysis used the full cohort. When using 
inverse probability of treatment weighting, observations with large weights may unduly 
influence results84,85. As a sensitivity test, we removed Veterans with an inverse probability of 
treatment weight greater than 20 and repeated the analysis, but the results did not qualitatively 
change. 
Instrumental Variable Analysis 
An instrumental variable (IV) analysis can identify the causal effect of an exposure on an 
outcome in the presence of unmeasured confounding if a valid instrument can be identified. An 
instrument is a variable that predicts exposure status, but does not affect the outcome except 
through exposure. More formally, the instrument must meet three conditions: (1) the instrument 
is strongly associated with the exposure (relevance), (2) the instrument has no causal effect on 
the outcome except through the exposure (the exclusion restriction), (3) and the instrument is not 
associated with unmeasured confounders of the outcome (exchangeability)86. Under these three 
conditions, an IV analysis can identify an upper and lower boundary of the average treatment 
effect. To identify a point estimate, we must also assume effect homogeneity, which is often 
unreasonable in practice. If we can assume monotonicity, we can estimate the local average 
treatment effect (LATE), which is the treatment effect among the compliers87. If an instrument is 
only weakly to moderately associated with the exposure, the resulting estimate of treatment 
effect may be biased as the conditions listed above are violated88. Even if the instrument is 
strongly associated with exposure, violations of the exchangeability assumption can cause bias. 
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To evaluate exchangeability, we constructed bias component plots for both the exposure and the 
instrument to visually evaluate possible exchangeability violations89,90.  
A possible instrument used in prior studies is provider or facility prescribing 
preference.91–95 This measures the likelihood that patients will be prescribed LTOT when treated 
at a given facility. We identified time-varying facility prescribing preference using the two-stage 
approach developed in the second aim of this work, which adjusts for Veteran characteristics and 
implements shrinkage to stabilize small cluster estimates. We used 4 previous quarters of data to 
generate the estimates, and chose an intermediate level of shrinkage with alpha == 0 and lambda 
== 10 for the shrinkage parameters in the elastic net model estimating observed over expected 
ratios.  
We implemented the two-stage least squares IV analysis. In the first stage, we fit a linear 
model with LTOT as the dependent variable, and home facility, Veteran chronic comorbidities, 
demographics, and chronic pain conditions as the independent variables. We evaluated the 
strength of the instrument using partial r-squared, F-statistic, and the risk difference associated 
with the instrument. We constructed bias component plots for both LTOT exposure and the 
instrument89,90. 
Software 
We used Microsoft Server Structured Query Language (SQL) for initial data 
management. We also used R Version 3.4.3 for data analysis, management, and visualization. 
Elastic-net general linear models were fit with the GLMNet package in R73. Random Forest 




 TRENDS IN THE PREVALENCE OF CHRONIC PAIN IN US VETERANS. 
Introduction 
Chronic pain is a leading public health issue in the United States (US), affecting up to 
100 million people at a potential cost of $635 billion USD1 . Epidemiologic studies have 
generally found that chronic pain rates are disproportionately higher among females, non-whites, 
and older patients3. Veterans as a group are more likely to report chronic pain4, and have high 
rates of diagnoses of pain-related conditions54,55. Despite the agreement amongst published work 
on disparities in chronic pain, reports of the prevalence of chronic pain have been inconsistent, 
ranging from under 10% to over 50%5,96. This variation in rates is partially due to the large 
variation in the approaches used to identify chronic pain. These approaches include 
representative survey samples directly asking about the impact and duration of pain, as well as 
analysis of electronic medical records of defined populations. Among studies leveraging 
electronic health records, diagnosis codes, pain scores, and opioid prescriptions have all been 
used to identify patients reporting chronic pain. Considering the heterogeneity in methods and 
the subsequent results, assimilating this body of knowledge is challenging.  
In 2011, the IOM released a report including a call to action for public agencies to study 
the impact and epidemiology of chronic pain in America.  In the 7 years since this call to action, 
there have only been a few national scope studies of the prevalence of chronic pain. As the 
largest integrated healthcare system in the United States serving 6 million unique Veterans per 
year, the Veterans Health Administration (VHA) is uniquely positioned to analyze the 
prevalence of conditions related to chronic pain in the context of other prevalent chronic 
diseases. The VHA has a robust, national electronic health record (EHR). In addition to 
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documenting encounters by assigning diagnostic codes, the VHA routinely collects pain scores 
for Veterans in outpatient and inpatient encounters. To our knowledge, there has been no prior 
study of chronic pain leveraging a longitudinal, national US cohort that could identify changes in 
the prevalence of chronic pain over time. Furthermore, any observed changes in the prevalence 
of chronic pain over time may be due to demographic changes in the underlying patient 
population. There is a need to identify longitudinal trends in the prevalence of chronic pain and 
other common chronic conditions in a large healthcare system, while considering the context of 
changing demographics on these trends.  
To fill this knowledge gap, we sought to identify the prevalence of chronic pain among 
Veterans receiving care at the VHA. We first describe the construction of a national cohort of 
Veterans receiving regular primary care between 2008-01-01 and 2015-06-01. We next identify 
Veterans in this cohort experiencing chronic pain based on (1) patterns of diagnostic codes for 
conditions related to chronic pain, or (2) Veteran reported pain scores. We then examine changes 
in the prevalence of chronic pain using pain scores alone, diagnostic codes alone, or the 
combination of both.  We also examine differences in the prevalence of chronic pain by age, 
race, gender, and across calendar time (2008-2015). We hypothesize that the period prevalence 
of chronic pain is increasing amongst Veterans engaged in primary care at the VHA, with female 
and non-white Veterans at an increased risk. We further hypothesize that this increase in the 
period prevalence of chronic pain is not explained by changes in VHA population demographics 




Study Setting and Cohort 
In this retrospective cohort study, we sought to identify the period prevalence of chronic 
pain among a cohort of all Veterans actively receiving primary care in the VHA health system 
between 2008-01-01 and 2015-06-01. This cohort comprised the population ‘at-risk’ for 
reporting chronic pain during the year following baseline date. We defined ‘active primary care’ 
as any primary care visit in the prior two years. Accordingly, we identified all Veterans with an 
outpatient primary care visit in the VHA between 2006-01-01 and 2015-06-01. Amongst those 
Veterans, we limited the cohort to Veterans with no recorded date of death prior to 2008-01-01. 
Outpatient visits were classified as primary care by clinic stop code using the VHA electronic 
healthcare record. The result of this algorithm identified Veterans with a record of primary care 
utilization no more than two years prior to the study start date of 2008-01-01. Veterans with 
missing values for gender, date of birth, race, or ethnicity were excluded from the study cohort. 
A small portion of Veterans were identified to have multiple values for race. These Veterans also 
had excessively higher observed utilization, leading to higher rates of all utilization based 
variables and outcomes. Accordingly, these Veterans were excluded from the study, as the most 
likely explanation is data or Veteran identifier errors.  
Study Design 
The primary interest of this analysis was to examine changes in the prevalence of chronic 
pain over time. In support of this, we discretized time into year-quarter combinations. For 
example: 2008, quarter one, covered the period between 2008-01-01 until 2008-03-31. For each 
Veteran at risk at the start of each year-quarter combination, we then assessed the period 
prevalence of chronic pain during the current quarter and following 4 quarters. We considered 
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Veterans to be at risk for chronic pain during a quarter if they had a primary care visit in the 2 
years prior to the start of a given quarter, and no reported date of death prior to the start of the 
quarter. If over two years passed since the last primary care visit, or a date of death was reported, 
Veterans were censored in the following quarter. Veteran demographics, comorbidities, and pain 
related variables were calculated for each quarter they were at risk as described below.  
Identifying Veteran Comorbidity and Demographics  
We identified chronic comorbidities using international classification of disease (ICD) 
diagnostic codes, including congestive heart failure, uncomplicated diabetes, complicated 
diabetes, lymphoma, metastatic cancer, obesity, chronic pulmonary disease, peripheral vascular 
disorders, renal failure, solid tumor without metastasis, valvular disease, and liver disease. We 
also identified suicidal ideation, suicide attempt or self-injury, organic or non-organic sleep 
disorders, post-traumatic stress disorder, traumatic brain injury, concussion, depression, anxiety 
disorder, schizophrenia and other psychotic disorders, bipolar or manic disorder, opioid use 
disorder, alcohol related disorders, and other substance abuse disorder. ICD9/10 codes for these 
conditions were grouped using the Agency for Healthcare Research and Quality (AHRQ) 
Clinical Classifications Software (CCS) combined with expert review of codes97. Following prior 
VHA studies6, we required one inpatient or two outpatient diagnoses on separate days between 
the prior 4 quarters and the quarter after the baseline date.  
Veteran demographics including age, race, ethnicity, gender, and urban/rural status were 
identified from the VHA central data warehouse. Age was calculated as of the first day of each 
quarter, and categorized into groups of 18-35, 35-45, 45-55, 55-65, 65-75, and 75+. Race and 
ethnicity were categorized into a single variable as white non-Hispanic, black non-Hispanic, 
Hispanic, and other.  
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Identifying Chronic Pain 
We sought to define Veterans reporting chronic pain by Veteran reported pain scores, as 
well as patterns of diagnostic codes. Chronic pain is commonly defined as pain lasting longer 
than 3 months71. The VHA regularly captures pain scores during encounters using the numeric 
pain rating scale, where 0 represents no pain, and 10 represents the worst possible pain. 
Following prior studies2,25,98, we defined pain scores of 1-3 as mild pain, pain scores of 4-6 as 
moderate pain, and pain scores of 7-10 as severe pain. To identify persistent pain, we identified 
Veterans reporting at least three pain scores of 4 or higher (moderate to severe pain), with at least 
30 days between the pain scores, but no more than 365 days between the first and last pain score. 
Veterans meeting this criterion were considered to reporting persistent moderate-severe pain. We 
repeated this algorithm for pain scores of 7 or higher to identify Veterans reporting persistent 
severe pain. Veterans meeting these criteria were considered as reporting persistent pain as of the 
date of the first pain score exceeding the cut-off.  
In addition to using pain scores to identify Veterans reporting chronic pain, we used 
diagnosis codes to identify Veterans with conditions likely to occur with chronic pain. 
Conditions were identified based on prior work2,25 and included joint pain, limb pain, back and 
neck pain, osteoarthritis and spondylosis, abdominal pain, headache and migraine, arthropathy, 
rheumatoid arthritis and inflammatory polyneuropathies, neuropathies, fibromyalgia, multiple 
sclerosis, painful bladder syndrome, genitourinary pain, multiple dystrophy, spinal cord injury, 
central pain syndrome, post-operative pain, and cancer pain. Veterans were required to have at 
least two diagnosis codes (inpatient or outpatient) with at least 90 days but no more than 365 
days between the diagnosis code dates. Veterans meeting this condition were considered as 
experiencing a chronic pain related condition as of the first diagnosis code.  
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We next identified if a Veteran was reporting persistent moderate-severe pain, reporting 
persistent severe pain, or experiencing a pain related condition during each quarter at risk. If a 
Veteran had a valid pain date as described above in the current quarter or prior 4 quarters, they 
were considered as reporting the pain condition of interest.  
Statistical Analysis 
We compared the distribution of comorbidities and Veteran demographics in table 1. We 
summarized continuous variables with the mean and standard deviation, and categorical 
variables with the frequency and proportion. Considering the large number of Veterans in the 
dataset and the lack of individual hypotheses corresponding to pairwise comparisons amongst 
Veteran traits, we did not include p-values for the pairwise comparisons made in table 1. Instead, 
we present standardized mean differences for 2008Q1, 2012Q1, and 2015Q1, with the reference 
group being 2008Q1. We took the average of the standardized mean differences.  We use a 
cutoff of 0.1 to identify covariates with notable imbalances72 across these time points. 
We sought to estimate the period prevalence of chronic pain as measured by pain scores, 
diagnoses, and the combination of either at the start of each calendar year-quarter. We first 
describe this by calculating the proportion of Veterans meeting the given chronic pain criteria 
each quarter, divided by the numbers of Veterans at risk each quarter. We next present 
descriptive visual summaries of the period prevalence over time, stratified by age, race, and 
gender in figures 3-5.  
We also sought to summarize the average change in the prevalence of chronic pain across 
time during the study period, adjusted for Veteran demographics (age category, race, gender). To 
estimate the adjusted prevalence ratio (risk ratio) of chronic pain associated with calendar time, 
we used a generalized linear model with a log link and a quasi-Poisson distribution. The 
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dependent variable was chronic pain defined by pain scores or diagnoses. In the first model, we 
used continuous calendar time as the independent variable. In the second model, we used 
continuous calendar time, age, race and gender as independent variables.  
Software 
We used Microsoft Server SQL for initial data management. We also used R Version 
3.4.3 for data analysis, management, and visualization.  
Results 
We identified 7,821,152 Veterans in active primary care between 2008-01-01 and 2015-
06-01 eligible for the study (Figure 1). The total follow-up time across these Veterans was 
37,811,156 person-years.  There were substantial changes in both the number of Veterans 
eligible, as well as the demographic composition of the cohort between 2008 and 2015. The 
number of eligible Veterans increased from 4,489,352 in 2008 to 5,494,268 Veterans in 2015Q2 
(table 1 and figure 2), a change of 22.4%.  The cohort became increasingly non-white and female 
during the study period. The age composition of the cohort shifted over time as well, with 
Veterans aged 18-35 and 65-75 becoming increasingly represented over time, while Veterans 
aged 45-55 and 75-89 were decreasingly represented.  
The prevalence of traditional chronic illnesses in this cohort were generally stable or 
decreasing over time (table 1). The prevalence of Cancer, dementia and diabetes was stable. The 
prevalence of cardiovascular disease, heart failure, pulmonary disorders, and peripheral vascular 
disease all decreased over the study period. The prevalence of liver disease increased modestly.  
Mental health disorders increased substantially over time (table 1). The prevalence of 
Anxiety disorder, bipolar disorder, depression and PTSD increased substantially during the 
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period. The prevalence of Schizophrenia declined modestly. The prevalence of suicidal ideation 
doubled during this period.  
Chronic Pain Conditions 
Table 2 summarizes the prevalence of chronic pain conditions from 2008 to 2015. As of 
2015, the most prevalent chronic pain conditions were musculoskeletal conditions--including 
back and neck pain (17%), joint pain (10.6%), and osteoarthritis (9.8%). Neuropathic conditions 
were moderately prevalent, with 4.5% of Veterans diagnosed. Gout, migraines/headaches, limb 
pain, arthropathy, abdominal pain and other pain were less prevalent (under 3%). Spinal cord 
injury, rheumatoid arthritis, multiple dystrophy, multiple sclerosis, fibromyalgia, genitourinary 
pain and bladder pain were all rare in this cohort (under 1%). There were large relative increases 
in the prevalence of back/neck pain, joint pain, headache/migraine, limb pain, abdominal pain, 
neuropathic pain, and other pain conditions from 2008 to 2015. The only pain condition with a 
decrease in prevalence was osteoarthritis, though the decrease was small (6% relative decrease). 
The prevalence of several rare pain conditions was stable over time, including bladder pain, 
genitourinary pain, gout, MS, MD, rheumatoid arthritis and spinal cord injuries. After combining 
these disease indicators into a single variable of ‘any chronic pain condition’, we found a 
prevalence of 30.1% in 2008Q1 which increased to 34.4% by 2015Q2. 
Pain Scores 
The prevalence of persistent moderate to severe pain (indicated by multiple elevated pain 
scores) was 16.6% in 2008Q1, and increased by a factor of 1.17 to 19.4% in 2015Q2. The 
prevalence of persistent severe pain was 7.9% in 2008Q1, and increased by a factor of 1.16 to 
9.2% in 2015Q2.  
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Chronic pain and demographics 
Figures 3-5 describe the period prevalence of chronic pain (by pain scores, diagnoses, or 
both) over time, stratified by Veteran demographics. In all cases, the trends in chronic pain were 
similar whether chronic pain was defined by persistent moderate to severe pain scores, persistent 
severe pain scores, any chronic pain diagnosis, or the combination of pain scores or diagnoses. 
The period prevalence of chronic pain differed across race, gender, and age category. Female 
Veterans were more likely to report chronic pain, and this difference did not change qualitatively 
through the study period (figure 3). White Veterans had the lowest prevalence of chronic pain, 
while black Veterans had the highest (figure 4). Age category had a non-linear association with 
the prevalence of chronic pain. Veterans aged 45 to 55 and 55 to 5 had the highest prevalence of 
chronic pain, while the youngest (18-35) and the oldest (75-120) had the lowest prevalence of 
chronic pain.  
Prevalence Ratio Models 
Using the quasi-Poisson general linearized model, we found the prevalence of chronic 
pain has increased by a factor of 8.6% between 2008 and 2015. After adjusting for changes in 
demographics listed in table 1, the increase in prevalence over the same time-period rose to 
10.5%. 
Discussion 
Using a national cohort of 7,821,152 million Veterans actively engaged in primary care at 
the VHA, we estimated that approximately 1 in 3 Veterans were diagnosed with a condition 
related to chronic pain, 1 in 5 Veterans report persistent moderate to severe pain, and 1 in 10 
Veterans report persistent severe pain as of 2015Q2.  We further found that the period prevalence 
of chronic pain among US Veterans receiving care at the VHA has modestly increased between 
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2008-01-01 and 2015-06-01, and this increase is not explained by changes in Veteran 
demographics. After adjusting for changes in demographics during this time frame, the increase 
in period prevalence was slightly higher.  
In 2011, an Institute of Medicine report on pain in America specifically called on federal 
institutions to ‘improve the collection and reporting of data on pain’1. The creation of this cohort 
and this study is a direct response to that call to action. To our knowledge, there has been no 
other national, longitudinal study estimating the prevalence of chronic pain among Veterans 
actively using primary care at the VHA. This study provides an important data point on the 
trends of the prevalence of chronic pain in that population. 
Estimates of the prevalence of chronic pain in general populations have varied widely, 
from under 10% to over 50%5,96. However, there is a paucity of Veteran specific estimates. The 
most relevant comparison is a study of 6,647 Veterans based on National Health and Nutrition 
Examination Survey (NHANES) data4. They found 65% of Veterans reported some amount of 
pain, while 9.1% of Veterans reported severe pain in the prior 3 months. The estimate for severe 
pain is consistent with our findings for persistent severe pain based on longitudinal pain scores. 
The other relevant study is a chart review of 300 randomly sampled US Veterans from 2002, 
which found that 50% of patients experienced one or more chronic pain conditions24.  Our study 
adds substantially to this prior work; our findings are based on the full cohort of Veterans 
receiving care at the VHA, and the longitudinal nature of the data allows estimation of temporal 
trends in the prevalence of chronic pain.   
Chronic pain is increasingly recognized as a major public health concern99. However, 
national US studies of the trends in the prevalence of chronic pain have been absent. Most prior 
work has focused on specific conditions or has not used national populations. For example, a 
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cross sectional survey repeated in 1992 and 2006 in North Carolina found the prevalence of 
chronic low back pain increased from 3.9% to 10.2%. A study using a national cohort of US 
Veterans diagnosed with musculoskeletal disorders concluded that ‘more than 50% of all 
Veterans receiving care in VHA facilities have diagnosed MSD’6; however, the study cohort did 
not include Veterans without MSD conditions. Our study allows unified estimates of the recent 
trends of multiple underlying conditions related to chronic pain, as well as the recent trends in 
Veteran reported pain through pain scores.  
Prior work among general populations has consistently found that female gender, non-
white race, and older age are associated with an increasing prevalence of chronic pain2,5,20,23,51,52. 
The disparities in the experience of chronic pain among Veteran specific populations have 
deviated from these findings. Using national US survey data, Nahin et al found older Veterans 
(60+) were less likely to report chronic pain than middles age Veterans4. This contrasted with the 
non-Veteran population, where older individuals were generally more likely to report chronic 
pain than younger individuals. The current study provides a comprehensive data point on the 
experience of chronic pain across demographics. Our findings regarding age and chronic pain are 
strikingly similar to the results presented by Nahin, where the oldest population of Veterans is 
actually at a decreased risk of reporting chronic pain. Our findings confirm that Female Veterans, 
on average, are at a higher risk of experiencing chronic pain compared with their male 
counterparts. Future work from this cohort will more extensively examine the differences in 
chronic pain across gender.  
Per the National Center for Veterans Analysis and Statistics, the number of Veterans 
alive in the US decreased by 8% between 2008 and 2015, with 21,578,655 Veterans in the US as 
of 2015. During the same period, this study identified a 22% increase in the number of Veterans 
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actively receiving primary care in the VHA. As of 2015Q2, there were 5,494,268 identified in 
the study cohort, representing 25% of all US Veterans. Despite a slight long-term decrease in the 
number of Veterans in the US, the VHA is caring for an increasingly large number of those 
Veterans. This study also provides insight into the changing healthcare needs of this population. 
Traditional chronic comorbidities are stable or decreasing in prevalence, while mental health 
conditions and pain related chronic diseases have been increasingly substantially. Current and 
projected Veteran healthcare needs and demand for services must be carefully examined as the 
VHA plans future allocation of healthcare resources between purchased community care and 
internal VHA care.  
Strengths and Limitations 
The primary strengths of this study were the large number sample size from a national 
cohort, and the multiple sources of administrative data used to identify chronic pain. To our 
knowledge, no prior work has integrated pain scores and diagnostic codes in a national cohort to 
estimate longitudinal trends in chronic pain. The primary limitation of this study is that all data 
used was collected for clinical and business use rather than research use. Another limitation is 
the inability of the VHA data to capture data from visits that occurred outside of the VHA 
healthcare system. We minimized this potential source of bias by requiring regular primary care 
visits as part of cohort eligibility.  
Conclusions 
In conclusion, this study finds that conditions related to chronic pain, as well as severe-
moderate persistent pain are common and increasing in prevalence among US Veterans. 
Traditional risk factors for chronic pain identified in other populations are identified in this 
cohort as well. Finally, the number of Veterans seeking care from the VHA is increasing 
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substantially. As a population, they are at an increasingly higher risk of mental health and 





Table 1. Demographics and clinical comorbidities by year. 
Variable 2008.Q1 2011.Q1 2015.Q2 SMD 
N 4489352 5014766 5494268  







race (%)    0.0519 
   black 665618 (14.8) 783904 (15.6) 924963 (16.8)  
   hispanic 273803 (6.1) 314073 (6.3) 369405 (6.7)  
   other 77686 (1.7) 99496 (2.0) 130385 (2.4)  







age (%)    0.2323 
   [18,35) 280654 (6.3) 410330 (8.2) 545692 (9.9)  
   [35,45) 299312 (6.7) 352262 (7.0) 430076 (7.8)  
   [45,55) 605964 (13.5) 645877 (12.9) 670399 (12.2)  







   [65,75) 865790 (19.3) 977269 (19.5) 
1642853 
(29.9)  







cancer (%) 298010 (6.6) 328855 (6.6) 366932 (6.7) 0.0062 
CVD (%) 184382 (4.1) 193521 (3.9) 205375 (3.7) 0.0039 
dementia (%) 49862 (1.1) 62842 (1.3) 66839 (1.2) 0.0022 





heart failure (%) 182820 (4.1) 190654 (3.8) 206431 (3.8) 0.0028 
ischemic heart disease (%) 683404 (15.2) 680114 (13.6) 643492 (11.7) 0.044 
liver (%) 9942 (0.2) 12766 (0.3) 15859 (0.3) 0.006 
liver - mild (%) 92238 (2.1) 108644 (2.2) 146990 (2.7) 0.0304 
pulmonary (%) 484475 (10.8) 529088 (10.6) 571230 (10.4) 0.004 
PVD (%) 177394 (4.0) 187973 (3.7) 202580 (3.7) < 0.001 
renal (%) 183245 (4.1) 234438 (4.7) 283166 (5.2) 0.0191 
anxiety (%) 222695 (5.0) 309809 (6.2) 477501 (8.7) 0.0859 
bipolar disorder (%) 109448 (2.4) 151228 (3.0) 175941 (3.2) 0.0073 
concussion (%) 2965 (0.1) 8144 (0.2) 8171 (0.1) 0.0012 
depression (%) 561945 (12.5) 726901 (14.5) 880787 (16.0) 0.0368 
ptsd (%) 353134 (7.9) 496416 (9.9) 668706 (12.2) 0.0601 
schizophrenia (%) 108153 (2.4) 111760 (2.2) 111399 (2.0) 0.0111 
TBI (%) 12959 (0.3) 16675 (0.3) 27470 (0.5) 0.0243 
sleep disorder (%) 288121 (6.4) 428617 (8.5) 729271 (13.3) 0.1332 




Table 1 (cont). Demographics and clinical comorbidities by year. 
Variable 2008.Q1 2011.Q1 2015.Q2 SMD 
subs. Abuse - opioid (%) 29315 (0.7) 41256 (0.8) 56700 (1.0) 0.018 
subs. abuse - other (%) 139884 (3.1) 178048 (3.6) 203832 (3.7) 0.0076 
suicideal ideation (%) 19521 (0.4) 39266 (0.8) 55152 (1.0) 0.0187 






Table 2. Chronic pain indicators by year.  
Variable 2008.Q1 2011.Q1 2015.Q2 SMD 
abdominal pain (%) 37614 (0.8) 49403 (1.0) 64201 (1.2) 0.0162 
arthropathy (%) 73828 (1.6) 69200 (1.4) 80008 (1.5) 0.0168 
back/neck pain (%) 572444 (12.8) 736036 (14.7) 932059 (17.0) 0.0551 
bladder pain (%) 649 (0.0) 878 (0.0) 1056 (0.0) 0.0018 
fibromyalgia (%) 21405 (0.5) 31149 (0.6) 34904 (0.6) < 0.001 
genitourinary pain (%) 1049 (0.0) 1211 (0.0) 2065 (0.0) 0.0061 
gout (%) 100127 (2.2) 114265 (2.3) 128485 (2.3) 0.0018 
headache/migraine (%) 88589 (2.0) 124105 (2.5) 164247 (3.0) 0.0302 
joint disorder (%) 338026 (7.5) 472248 (9.4) 584556 (10.6) 0.0306 
limb pain (%) 36373 (0.8) 48245 (1.0) 116210 (2.1) 0.0865 
multiple sclerosis (%) 11054 (0.2) 11886 (0.2) 13096 (0.2) < 0.001 
multiple dystrophy (%) 792 (0.0) 931 (0.0) 1015 (0.0) < 0.001 
neuropathy (%) 138781 (3.1) 178888 (3.6) 247266 (4.5) 0.0384 
osteoarthritis (%) 472363 (10.5) 518054 (10.3) 538990 (9.8) 0.0088 
other pain (%) 22205 (0.5) 63340 (1.3) 124409 (2.3) 0.0624 
rheum. arthritis (%) 29689 (0.7) 31933 (0.6) 35072 (0.6) < 0.001 
spinal cord injury (%) 5128 (0.1) 5429 (0.1) 6025 (0.1) < 0.001 
total pain conditions  (mean (sd)) 0.43 (0.78) 0.49 (0.85) 0.56 (0.94) 0.0689 














persistent moderate-severe pain score 
(%) 744176 (16.6) 935916 (18.7) 
1065625 
(19.4) 0.0152 
































 AN ENSEMBLE APPROACH TO ESTIMATING LONGITUDINAL FACILITY 
PRESCRIBING BEHAVIOUR FOR USE AS AN INSTRUMENT 
Introduction 
Which treatment a patient receives and the probability they experience a bad outcome can 
differ based on where they received medical care100. Discussions about how to accurately 
measure quality in healthcare have been occurring for over 20 years101,102. Identifying providers 
or hospitals with low or high patient treatment and outcome probabilities is often called ‘provider 
profiling’101. It has long been recognized that statistical approaches to provider profiling should 
adjust for possible confounding by patient mix. Providers that care for high-risk patients may 
have measurably different patient treatment patterns and worse patient outcomes because their 
high-risk patients are more likely to have bad outcomes. Another challenge in provider profiling 
arises from sampling variation in the presence of uneven cluster sizes. Providers with a low 
number of patients may have extreme average treatment or outcome measures by chance alone. 
One approach to overcoming sampling variation is to share information between clusters, 
effectively ‘shrinking’ the information about one provider towards the sample average to 
stabilize the estimate. Statistical estimators with this property are termed ‘shrinkage estimators’, 
and include random effects models77,78, Bayesian inference via priors79, regularized general 
linear models73,80, and empirical shrinkage estimators81. While there seems to be consensus that 
methods without shrinkage properties are overly sensitive to small clusters, comparisons of these 
methods have found existing shrinkage may be overly insensitive to identifying outliers among 
small clusters102,103.  
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Estimates of the variation in physician or facility level treatment preferences can be used 
to identify causal relationships between treatment and outcome in observational data by 
implementing an instrumental variable (IV) analysis. An instrumental variable analysis seeks to 
identify a so-called ‘instrument’, which is a variable that is strongly related to exposure, but 
unrelated to the outcome except through the exposure. Prescribing preference among physicians 
or facilities has been proposed in prior studies as a possible instrument to study treatment-
outcome relationships91–95. If there is significant variation in treatment exposure that is 
attributable to the physician’s therapeutic preference, comparing the outcomes of patients of 
‘low’ and ‘high’ prescribers can establish causal relationships between exposure and outcome. 
Prior to implementing the prescribing-preference IV analysis, the analyst must identify the 
instrument.  
Prior studies have used descriptive aggregations of facilities’ prior prescribing behavior 
as the instrument92,93,95,104,105. One such approach is to calculate the average rate of exposure 
among prior patients in a fixed period. There are two issues with using such an approach. First, 
patients may not be randomly distributed among facilities. If patients who are at a higher risk of 
LTOT are unevenly distributed among facilities, we may erroneously attribute variation in LTOT 
rates to facilities that are simply taking care of high-risk patients. Second, the absolute number of 
patients per site may be unevenly distributed. Facilities with a smaller number of patients will 
have more sampling variation and thus may be erroneously labeled as high or low prescribers. To 
our knowledge, no prior work has evaluated the impact of applying shrinkage and case 
adjustment on estimates of prescribing preference for use in an instrumental variable analysis.  
To fill this gap, we developed, implemented and evaluated a novel method to identify 
facility prescribing preference using longitudinal prescribing data. The method uses prior patient 
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level prescribing data to identify facility-level prescribing preference. The method can use 
multiple prior periods of data, different models to adjust for patient case mix, and the degree of 
shrinkage can be specified as a parameter. Using this ensemble method, we evaluated the 
accuracy of the resulting prescribing preference estimates when (1) using 1-4 prior quarters of 
patient level data, (2) using flexible machine learning approaches to patient mix adjustment, and 
(3) using different degrees of shrinkage to stabilize facility estimates.  Using a national cohort of 
US Veterans engaged in primary care with the VHA and reporting incident chronic pain between 
2008-2015, we identified exposure to long term opioid therapy. We sought to estimate time-
varying facility prescribing preference of LTOT among the VHA facilities where these Veterans 
receive care. We hypothesize that the approach yielding the best prediction of subsequent 
exposure (and therefore the optimal facility prescribing preference estimator) will be a non-
parametric/flexible model of expected exposure rates by site, using multiple prior time points, 
and with shrinkage applied to longitudinal site level estimates.  
Methods 
We sought to implement a novel combination (‘ensemble’) of algorithms to use prior 
patient level prescribing data to estimate facility level prescribing preference. In this methods 
section, we first describe the population of study participants and the construction of key 
variables. We then describe the statistical analyses exploring the population composition. Next, 
we describe the ensemble in detail. We close this section by describing the strategy for 





In this retrospective cohort study, we first sought to identify a longitudinal cohort of US 
Veterans who are engaged in regular primary care in VHA facilities and experiencing incident 
chronic pain. We defined incident chronic pain based on either persistently elevated self-reported 
pain scores, or multiple diagnoses of conditions related to chronic pain (further details below). 
We first identified all Veterans engaged in active primary care at the start of each fiscal-year 
quarter. We defined ‘active primary care’ as any primary care visit in the two years prior to the 
start of each fiscal-year quarter. Accordingly, we identified all Veterans with an outpatient 
primary care visit in the VHA between 2006-01-01 and 2015-07-01. Amongst those Veterans, 
we limited the cohort to Veterans with no recorded date of death prior to 2008-01-01. Outpatient 
visits were classified as primary care by clinic stop code using the VHA electronic healthcare 
record. We identified the first quarter in which a Veteran reported chronic pain, and considered 
the first day of this quarter to be the Veteran’s baseline date. If a Veteran reported chronic pain 
in any of the quarters between 2006 and 2008, they were considered prevalent cases and 
excluded from the study (a two-year washout period). Veterans with missing values for gender, 
date of birth, race, or ethnicity were excluded from the study cohort. A small portion of Veterans 
were identified to have multiple values for race. These Veterans also had excessively higher 
observed utilization, leading to higher rates of all utilization-based variables and outcomes. 
These Veterans were excluded from the study, as the most likely explanation is data or Veteran 
identifier errors. Veterans were censored from the study at the time of death, or if more than two 
years passed from the last primary care visit. Veterans without four full quarters of follow-up 
following baseline were excluded from the study. Veterans were linked to their home primary 
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care facility as described below. Veterans whose home primary care facility was a medical 
center, outpatient clinic or health care center were included in the study.  
Identifying Home Facility and Facility Traits 
Each Veteran was assigned to a home facility based on patterns of primary care visits in 
the 4 quarters preceding baseline, and the quarter including baseline. We extracted all outpatient 
visits occurring in primary care clinics as indicated by clinic stop codes. We then aggregated 
these visits by facility identifier, and took the most frequently occurring facility as the ‘home 
facility’. Type and rurality of facility was used in the analysis. Facilities were classified as 
medical centers, urban community-based outpatient clinics, or rural community-based outpatient 
clinics. Urban/rural status of facilities is maintained by the VHA Planning Systems and Support 
Group.  
Long Term Opioid Therapy 
Long term opioid therapy was defined as 90 or more days supply of opioids within any 
365-day period. The opioids included butorphanol, codeine, fentanyl, hydrocodone, 
hydromorphone, levorphanol, meperidine, morphine, oxycodone, oxymorphone, pentazocine, 
propoxyphene, tapentadol, or tramadol. A veteran was considered exposed to long term opioid 
therapy as of the first day of the first prescription meeting the criteria above.  
Identifying Veteran Comorbidity and Demographics  
We identified chronic comorbidities using international classification of diseases (ICD) 
diagnostic codes, including congestive heart failure, uncomplicated diabetes, complicated 
diabetes, lymphoma, metastatic cancer, obesity, chronic pulmonary disease, peripheral vascular 
disorders, renal failure, solid tumor without metastasis, valvular disease, and liver disease. We 
also identified suicidal ideation, suicide attempt or self-injury, organic or non-organic sleep 
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disorders, post-traumatic stress disorder, traumatic brain injury, concussion, depression, anxiety 
disorder, schizophrenia and other psychotic disorders, bipolar or manic disorder, opioid use 
disorder, alcohol related disorders, and other substance abuse disorder. ICD9/10 codes for these 
conditions were grouped using the Agency for Healthcare Research (AHRQ) Clinical 
Classifications Software (CCS) combined with expert review of codes97. Following prior VHA 
studies6, we required one inpatient or two outpatient diagnoses on separate days between the 
prior 4 quarters and the quarter after the baseline date.  
Veteran demographics including age, race, ethnicity, gender, and urban/rural status were 
identified from the VHA central data warehouse. Age was calculated as of the first day of each 
quarter, and categorized into groups of 18-35, 35-45, 45-55, 55-65,65-75, and 75+. Race and 
ethnicity were categorized into a single variable as white non-Hispanic, black non-Hispanic, 
Hispanic, and other.  
Identifying Chronic Pain 
We sought to define Veterans reporting chronic pain by Veteran reported pain scores, as 
well as patterns of diagnostic codes. Chronic pain is commonly defined as pain lasting longer 
than 3 months71. The VHA regularly captures pain scores during encounters using the numeric 
pain rating scale (REF), where 0 represents no pain, and 10 represents the worst possible pain. 
Following prior studies (REF), we defined pain scores of 1-3 as mild pain, pain scores of 4-6 as 
moderate pain, and pain scores of 7-10 as severe pain. To identify persistent pain, we identified 
Veterans reporting at least three pain scores of 4 or higher (moderate to severe pain), with at least 
30 days between the pain scores, but no more than 365 days between the first and last pain score. 
Veterans meeting this criterion were considered to reporting persistent moderate-severe pain. We 
repeated this algorithm for pain scores of 7 or higher to identify Veterans reporting persistent 
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severe pain. Veterans meeting these criteria were defined as reporting persistent pain as of the 
date of the first pain score.  
In addition to using pain scores to identify Veterans reporting chronic pain, we used 
diagnosis codes to identify Veterans with conditions likely to occur with chronic pain. 
Conditions were identified based on prior work2,25 and included joint pain, limb pain, back and 
neck pain, osteoarthritis and spondylosis, abdominal pain, headache and migraine, arthropathy, 
rheumatoid arthritis and inflammatory polyneuropathies, neuropathies, fibromyalgia, multiple 
sclerosis, painful bladder syndrome, genitourinary pain, multiple dystrophy, spinal cord injury, 
central pain syndrome, post-operative pain, and cancer pain. Veterans were required to have at 
least two diagnosis codes (inpatient or outpatient) with at least 90 days but no more than 365 
days between the diagnosis code dates. Veterans meeting this condition were defined as 
experiencing a chronic pain related condition as of the first diagnosis code.  
We next identified if a Veteran was reporting persistent moderate-severe pain, reporting 
persistent severe pain, or experiencing a pain related condition during each quarter at risk. If a 
Veteran had a valid pain date as described above in the current quarter or prior 4 quarters, they 
were considered reporting the pain condition of interest.  
Descriptive Analysis 
We compared the distribution of comorbidities and Veteran demographics in table 1. We 
summarized continuous variables with the mean and standard deviation, and categorical 
variables with the frequency and proportion. Considering the large number of Veterans in the 
dataset and the lack of individual hypotheses corresponding to pairwise comparisons amongst 
Veteran traits, we did not include p-values for the pairwise comparisons made in table 1. Instead, 
we present standardized mean differences for 2008Q1, 2012Q1, and 2015Q1, with the reference 
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group being 2008Q1. We took the average of the standardized mean differences.  We use a 
cutoff of 0.1 to identify covariates with notable imbalances across these time points72. 
Study Design  
The overall goal of this study is to evaluate the accuracy of a novel ensemble of 
algorithms that uses longitudinal Veteran-level exposure data (the input) to estimate longitudinal 
facility level prescribing behavior (the output). We used a retrospective cohort study design, 
where the input cohort included Veterans in regular primary care reporting incident chronic pain. 
Follow-up time was discretized into fiscal-year quarters. The baseline date for each Veteran was 
the first day of the quarter in which they reported incident chronic pain. We examined the 2 
quarters after baseline to identify if each Veteran was exposed to long term opioid therapy. Each 
Veteran was assigned to a ‘home facility’ based on primary care visits as described above. The 
final input dataset therefore included one row for each Veteran, with the following variables: 
baseline fiscal-year quarter, LTOT exposure in the subsequent two quarters, home facility, 
Veteran level covariates and facility level covariates.  
Estimating Facility-prescribing Preference Via a Novel Ensemble of Algorithms 
Overview 
We used a novel two-stage ensemble to estimate the time-varying ‘prescribing 
preference’ for each VHA facility using Veteran level longitudinal prescribing data as the input. 
The output of the ensemble is longitudinal facility level estimates of ‘prescribing-preference’, 
indicating if a facility is an above or below average prescriber. We summarized facility level 
‘prescribing-preference’ as observed over expected ratios, thus the final output of the ensemble is 
longitudinal estimates of facility observed over expected ratios.  
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The two-stage ensemble is summarized in figure 4. In the first stage, we estimated the 
Veteran level probability of LTOT exposure for each Veteran. We then aggregated the Veteran 
level data to observed over expected ratios for each facility and year-quarter based on those 
estimates. In the second stage, we implemented a regularized generalized linear model to 
stabilize the facility-level observed over expected estimates.  
Stage 1: Estimating Veteran LTOT Exposure  
We expect simple estimators such as raw LTOT fractions (Observed number of veterans 
with LTOT exposure divided by Number of veterans at risk) to exhibit bias due to (1) uneven 
Veteran case mix, and (2) uneven cluster sizes. We addressed uneven Veteran case mix in Stage 
1 by estimating the probability of LTOT exposure for each Veteran, conditioning on Veteran 
demographics and comorbidities (i.e., adjusting for patient mix). We then calculated observed 
over expected (O/E) ratios of LTOT for each facility, with O as the observed number of LTOT 
cases and calculating the ‘expected’ number of LTOT cases (E) at each facility as the sum of the 
probabilities of LTOT exposure over veterans at that facility. This resulted in an observed over 
expected ratio for each facility and year-quarter combination.  
We considered several methods for calculating the sum E.  Accurately estimating the 
Veteran level probability of LTOT exposure conditional on Veteran traits requires correctly 
specifying an underlying model. Since the underlying model is unknown, we considered 
different possible models. The four models included A) a null model for comparison purposes, 
where the predicted probability of LTOT was simply the average population exposure (no case 
mix adjustment), B) a logistic regression, C) an elastic-net regularized logistic regression73, and 
D) a random forest74. This resulted in 4 distinct methods for estimating the expected probability 
of Veteran-level LTOT exposure for use in the observed over expected ratios. We identify the 
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choice method as ensemble parameter mod.  These methods are summarized in the top panel of 
Figure 2. 
Since we are interested in accurate prediction rather than inference, we used a machine 
learning approach to maximize the predictive ability of the four different models. We 
implemented 10-fold cross validation75 using area-under-the curve (AUC) calculations to 
optimize model hyperparameters as needed.  For the elastic net, we considered alpha values of 0, 
0.25, 0.5, 0.75, and 1. For the random forest, we considered mtry values  of 2, 4, 6, and 10. Due 
to computing constraints, the initial hyperparameter search for the random forest model was 
developed on a random sample of 50,000 Veterans. After selecting mtry using that sample, we 
implemented the random forest on a random sample of 1,000,000 Veterans. We present the AUC 
calculations for the full cohort using these 4 final models for descriptive purposes (these AUC 
calculations were not used for model or hyperparameter selection).  
Stage 2: Shrinkage of Facility O/E Ratios 
In Stage 2 of the ensemble, we sought to address potential bias in the observed over 
expected ratios due to small cluster sizes (i.e., facilities with a small number of Veterans in a 
year-quarter). The ensemble included 1 to 4 prior quarters of facility O/E ratios to stabilize the 
facility estimates (ensemble parameter n), since including more prior data may stabilize facility 
estimates. We also implemented varying degrees of shrinkage to stabilize the facility O/E ratios, 
further described below.  
Shrinkage Estimators 
Methods for stabilizing estimates in sparse data typically leverage information sharing 
from other closely related data points, where the degree of relatedness is inferred from the 
structure of the data. If there are repeated measurements on a single unit, prior measurements 
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that are close in time may be correlated with the current measurement of the same unit. 
Similarly, if a unit is part of a cluster of other similar units (such as medical facilities), we may 
infer the unit is correlated with other units to some degree. If there are clusters of correlated 
observations as described, the accuracy of predictions of an individual cluster can be improved 
by sharing information among clusters, or within a single cluster over time. Estimators that share 
information in this way are referred to as ‘shrinkage estimators’76, since the observed cluster 
average is being ‘shrunk’ towards the average of other data points. Estimators with this behavior 
have been proposed and implemented extensively using different frameworks and under different 
names, including random effects models77,78, Bayesian inference via priors79, regularized general 
linear models73,80, and empirical shrinkage estimators81.  
In this ensemble, we estimated facility observed over expected ratios of LTOT exposure 
using data on observed and expected LTOT exposure in prior quarters. We implemented Poisson 
generalized linear models with elastic-net regularization73 , where the degree of shrinkage can be 
specified as lambda, and the shape of the shrinkage can be specified as alpha. We sought to 
describe the impact of varying the degree of shrinkage both within facility across time, and 
between facilities for a single point in time. 
To estimate the observed over expected ratios for each facility in each year quarter, we 
used separate Poisson generalized linear models with elastic-net regularization for each year 
quarter. The dependent variable was the observed number of Veterans exposed to LTOT in the 
prior year-quarter(s), and a log offset of the expected number of Veterans exposed to LTOT in 
the prior year quarter(s) was added to the model. The expected number of Veterans exposed to 
LTOT in each prior year-quarter was calculated as the sum of the individual Veteran expected 
probabilities of LTOT for each facility. Since there were four different methods implemented to 
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estimate the Veteran level probability of LTOT exposure, this modeling process was repeated 
four times, once for each of those methods. For each year-quarter between 2009-01-01 (2009Q1) 
and 2015-06-01 (2015Q2), we repeated this approach using 1, 2, 3, or 4 prior quarters of data to 
estimate the observed over expected ratio for each facility. When only one prior quarter was 
used, the elastic-net regularized Poisson GLM included home facility as an independent 
categorical predictor coded with a referent group. This is conceptually parallel to a random 
intercept under a generalized linear modeling approach. When more than one prior quarter was 
used, the elastic-net regularized Poisson GLM included facility, time, and a facility by time 
interaction term. In this model, the time parameter was not subjected to regularization, but the 
facility and time by facility interaction terms were subjected to regularization. This is 
conceptually similar to including a random intercept and random slope under a generalized linear 
modeling approach.  
The appropriate degree (strength) of shrinkage for the time varying facility observed over 
expected estimates is unknown. Since we used an elastic net regularization, the degree and shape 
of shrinkage can be controlled via the alpha and lambda parameters used in the regularizing 
function. Alpha includes values between 0 and 1, with 0 corresponding to a LASSO regression 
and 1 corresponding to a ridge regression. Lambda includes values of 0 or greater, with 0 
indicating no shrinkage, and increasing values of lambda indicating stronger shrinkage. In this 
ensemble, we considered values of 0, 0.25, 0.5, 0.75, and 1 for alpha and values of 0.001, 0.01, 
0.1, 0.5, 1, 5, 10, 50, 250, and 500 for lambda. 
Combining Stage 1 and 2 
The entire algorithm for estimating a time varying facility level observed over expected 
ratio is summarized in figure 2. In stage 1, we must choose between the four modeling 
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approaches to estimate Veteran level LTOT exposure (parameter mod). In Stage 2, we must 
choose whether to use 1, 2, 3, or 4 prior quarters of data to estimate the current quarter 
(parameter n) and we must choose the degree and shape of shrinkage (parameters lambda and 
alpha). This resulted in 800 possible parameter combinations. Each combination of parameters 
results in a distinct set of estimated facility observed over expected ratios, which is the output of 
the ensemble.  
Selecting the Optimal Ensemble Parameters 
We next sought to compare these approaches to estimating prescribing behavior and 
identify which approach gives the optimal estimate. Although the true value of facility 
prescribing behavior is unknown, we observe the LTOT exposure status of Veterans at each 
facility. We define the optimal estimate of facility prescribing behavior to be the estimate 
resulting in the most accurate prediction of subsequent Veteran-level LTOT exposure.  
For each facility and year-quarter combination, we estimated the observed over expected 
ratio of LTOT exposure based on data from the prior year as described above (using the 
ensemble).  The resulting facility-level estimate was then used to predict LTOT exposure among 
Veterans newly reporting incident chronic pain at the same facility. Since the outcome in these 
models (Veteran-level LTOT exposure) is binary, we fit a Veteran-level logistic regression with 
LTOT exposure as the dependent variable, and facility observed over expected ratio discretized 
into quintiles as the independent variable. This model was adjusted for Veteran demographics, 
chronic comorbidities, and chronic pain conditions as described above.  We identified the 
deviance (-2 log-likelihood) associated with the facility observed over expected ratio term in the 
model. We then repeated this approach for each combination of ensemble parameters (described 
in figure 2) and explored the change in deviance based on using different combinations of 
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ensemble parameters. The optimal combination of ensemble parameters was identified based on 
the lowest deviance. 
Software 
We used Microsoft Server SQL for initial data management. We also used R Version 
3.4.3 for data analysis, management, and visualization. Elastic-net general linear models were fit 




After applying study exclusion criteria, we identified 2,229,166 Veterans in active 
primary care between 2008-01-01 and 2015-06-01 and reporting incident chronic pain. This 
cohort of Veterans was demographically similar to previously described Veteran cohorts6. Table 
1 summarizes the demographics, pain related conditions, mental health comorbidities, and 
chronic comorbidities in the cohort. The cohort was predominately male gender and white race. 
The musculoskeletal disorders were relatively common, including back/neck pain, joint 
disorders, and osteoarthritis. Depression was the most common mental health disorder, followed 
by post-traumatic stress disorder. A little over half the cohort received primary care at medical 
centers, while a third received primary care at urban community based clinics. The remaining 
10% received care in rural community based clinics.  
Long Term Opioid Therapy Exposure 
Exposure to long term opioid therapy was uncommon, with 13% of the cohort exposed to 
LTOT. A comparison of Veteran traits stratified by exposure to LTOT is presented in table 1. 
Veterans exposed to LTOT were disproportionately male gender, white race, age 45-65. Among 
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pain conditions, Veterans exposed to LTOT were more likely to be diagnosed with back/neck 
pain or other pain. Veterans exposed to LTOT were less likely to be diagnosed with gout or 
neuropathies. Among mental health conditions, depression was associated with higher rates of 
LTOT exposure. Among chronic comorbidities, only pulmonary disorders were associated with 
an increase in LTOT exposure.  
VHA Facilities and LTOT 
In this work, we sought to estimate the facility prescribing preference over time. First, we 
describe the distribution of Veterans by facility (figure 3) and the distribution of unadjusted 
facility level LTOT exposure over time (figure 4). Figure 4 shows the total number of Veterans 
at each facility is skewed, with most facilities having a smaller number of Veterans. Figure 5 
shows the raw LTOT exposure rate at each facility for each calendar year-quarter. Each line is a 
distinct facility, and the bottom and top quartiles as of 2008-01-01 are color coded. The figure 
shows there is an overall trend of decreasing LTOT exposure in the system from 2008 to 2015. 
There is wide variation at the facility level, with some facilities having exposure rate of 0, while 
other have exposure rate above 50%. The color distribution shows moderate consistency from 
2008 to 2015, indicating facilities are somewhat stable in their bottom/top quartile status over 
time.  
Performance of Model Ensemble across Parameters  
We sought to explore the impact on the predictive value of the ensemble by choosing 
values for the following model hyperparameters. There were 4 model hyperparameters 
(summarized in figure 2): 
1. Choice of model to estimate Veteran level LTOT exposure (model in stage 1) 
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2. How many quarters of prior data to use when estimating facility LTOT behavior (n in 
stage 2) 
3. How strong of shrinkage should be enforced (lambda in stage 2) 
4. What shape of shrinkage should be enforced (alpha in stage 2) 
The optimal predictive value was obtained by using the following combination of 
hyperparameters: (1) GLM-NET model to estimate Veteran level LTOT (model = GLM-NET), 
(2) four prior quarters of prescribing data (n = 4), (3) intermediate degree of shrinkage (lambda = 
10), and (4) a ridge regression in stage 2 (alpha = 0). This resulted in a deviance of 30,299.47, 
which is an 11% increase from the deviance obtained using no adjustment (null model), no 
shrinkage (lambda = 0 and alpha = 0), and only a single prior quarter of prescribing data 
(deviance = 27,256.24).  
Figure 5 shows the deviance values for all model hyperparameter combinations. If only 
one prior quarter of prescribing data was used in the algorithm (n = 1), the degree of shrinkage 
had a small positive effect on the deviance for low to intermediate values of shrinkage. For 
higher values of shrinkage, the deviance decreased substantially. Adding more information into 
the model by increasing the number of prior quarters (n > 1) included increased the deviance, but 
only if an intermediate amount of shrinkage was included in the model. The choice of model to 
estimate Veteran level LTOT exposure had little impact on the deviance values, unless the 
random forest was used (model = random forest). The random forest model performed 
significantly worse than the other options (model).  The null model, the generalized linear model, 
and the elastic-net generalized linear model all performed similarly, though the elastic-net model 





Accurately identifying facility level variation in treatment is challenging due to sampling 
variation inherent in smaller facilities, and a potentially uneven mixture of high and low risk 
patients at facilities. If the data under study is longitudinal, identifying facility behavior is further 
challenged by deciding how much prior data should be used, and how to integrate prior data into 
the estimates. In this work, we propose a novel ensemble of existing statistical algorithms to 
identify time-varying facility prescribing preference of long term opioid therapy. We first 
identified a national dataset of over 2 million Veterans reporting incident chronic pain in regular 
care at VHA facilities between 2008 and 2015, and then used this data to test the proposed 
ensemble. The optimal ensemble used a penalized logistic regression to adjust for case mix, 4 
prior quarters of information, and a moderate degree of shrinkage to stabilize the facility 
estimates.  
Prior work has recognized the issues of variable cluster sizes and uneven distributions of 
high risk patients among hospital when studying hospital level behavior. Stabilizing smaller 
cluster sizes is accomplished through sharing information between clusters, or by using multiple 
longitudinal data points of a single cluster. Estimators with this property are called ‘shrinkage’ 
estimators76. Estimators with this behavior have been proposed and implemented extensively 
using different frameworks and under different names, including random effects models77,78, 
Bayesian inference via priors79, regularized general linear models73,80, and empirical shrinkage 
estimators81. Random effects models can simultaneously adjust for case mix by conditioning on 
patient level covariates and then estimating facility level offsets via specification of random 
effects. These random effects models have two fatal flaws in the context of the current work: the 
degree of shrinkage cannot be specified, and the convergence of the algorithms is unacceptably 
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slow in high dimensional data. Use of Bayesian inference and specification of priors on the 
cluster level model terms allows flexibility in specifying the degree of shrinkage by using 
stronger or weaker priors. However, convergence of the models is also unacceptably time-
consuming in high-dimensional data. The ensemble proposed in this work overcomes both of 
those limitations; the degree of shrinkage can be specific through the parameterization of the 
elastic-net model in stage 2, and the time to convergence is acceptable in high dimensional data.   
The importance of flexibility in specifying the degree of shrinkage is highlighted by this 
work. To our knowledge, this is the first report to explicitly study the effect of different degrees 
of shrinkage on the accuracy of prescribing-preference estimates. Figure 5 shows the relationship 
between degree of shrinkage, and the accuracy of the prescribing preference estimates. If there is 
effectively no shrinkage applied (lambda << 0.01), then including more prior quarters of data 
does not improve the accuracy of the estimates. However, if a moderate degree of shrinkage is 
applied (lambda =10, alpha = 0), the predictive accuracy is maximized. We conclude that 
including more prior data on hospital behavior can increase the accuracy of prescribing 
preference estimates, but only if an appropriate degree of shrinkage is implemented.  
This proposed ensemble is particularly useful in the context of instrumental variable 
analysis using prescribing preference as an instrument. Instrumental variable analysis is a 
method to make causal inference about exposure--outcome relationships in observational data. 
Instrumental variable analysis requires identifying a valid instrument, which is a variable that is 
associated with the exposure, but not associated with the outcome other than through the 
exposure. Physician or facility prescribing preference has been identified as a potentially valid 
instrument and used in prior studies91–93,95,106. If there is variation in the choice of therapy among 
medical providers that is unrelated to patient traits (so called prescribing preference), an IV 
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analysis can use this variation to make causal inference on treatment exposure and outcomes. 
Maximizing the accuracy of estimates of prescribing preference is vital in an IV analysis, since 
stronger IV’s have more statistical power and are less biased by misspecification of the models 
used in the IV analysis107.   
Our choice of estimating observed over expected ratios to summarize facility prescribing 
preference is both a strength and a weakness of this ensemble method. Summarizing hospital 
behavior as an observed over expected ratio is easy to interpret: values above 1 indicate a higher 
than average prescribing preference, and values below 1 indicate a lower than average 
prescribing preference. Modeling observed over expected ratios is also convenient using a 
generalized linear modeling framework with a log link and Poisson family. This also enables use 
of the GLM-NET regularization of the Poisson generalized linear model. In the motivating 
example, we sought to identify high and low prescribers for use in a subsequent IV analysis, thus 
we were only interested in estimating relative prescribing preference. This ensemble is not 
appropriate if one is interested in estimating the absolute probability of exposure at a given 
facility, as the observed over expected ratios are only relative to the average.  
In summary, the proposed ensemble approach gave more accurate estimates of 
prescribing preference than simple descriptive summaries of prior prescribing behavior. 
Separating the case mix adjustment stage from the shrinkage stage allowed the flexibility of 
testing different machine learning approaches to adjust for variation in case mix in the first stage. 
Aggregating the resulting dataset into facility level observed over expected ratios and using 
regularized regression to achieve shrinkage was effective in large dimensional data and resulted 




























Table 1. Veterans Traits across long term opioid therapy exposure (LTOT) 
Variable No LTOT LTOT SMD 
n 1935743 293423  
Home Facility Type (%)   0.021 
   Medical Center 1085080 (56.1) 165204 (56.3)  
   Rural CBOC 186758 (9.6) 29829 (10.2)  
   Urban CBOC 663905 (34.3) 98390 (33.5)  
Male gender (%) 1773563 (91.6) 273585 (93.2) 0.061 
race (%)   0.117 
   black 358255 (18.5) 45546 (15.5)  
   hispanic 135376 (7.0) 16557 (5.6)  
   other 47402 (2.4) 5219 (1.8)  
   white 1394710 (72.1) 226101 (77.1)  
age (%)   0.228 
   [18,35) 275013 (14.2) 36151 (12.3)  
   [35,45) 199764 (10.3) 30419 (10.4)  
   [45,55) 306572 (15.8) 60775 (20.7)  
   [55,65) 547249 (28.3) 98338 (33.5)  
   [65,75) 325715 (16.8) 38922 (13.3)  
   [75,120] 281430 (14.5) 28818 (9.8)  
Joint disorder (%) 449382 (23.2) 63060 (21.5) 0.041 
Osteoarthritis (%) 303760 (15.7) 44140 (15.0) 0.018 
back/neck pain (%) 534543 (27.6) 122500 (41.7) 0.300 
abdominal pain (%) 37075 (1.9) 4468 (1.5) 0.030 
arthropathy (%) 43024 (2.2) 6635 (2.3) 0.003 
other pain (%) 16418 (0.8) 10274 (3.5) 0.183 
gout (%) 95778 (4.9) 5835 (2.0) 0.162 
limb pain (%) 43652 (2.3) 4850 (1.7) 0.044 
Neuropathy (%) 110769 (5.7) 11419 (3.9) 0.086 
headache/migraine (%) 116041 (6.0) 14168 (4.8) 0.052 
rheum. arthritis (%) 14073 (0.7) 2243 (0.8) 0.004 
fibromyalgia (%) 10857 (0.6) 2494 (0.8) 0.035 
MS (%) 4992 (0.3) 463 (0.2) 0.022 
spinal cord injury (%) 1357 (0.1) 410 (0.1) 0.022 
multiple dystrophy (%) 575 (0.0) 42 (0.0) 0.010 
genitourinary pain (%) 1013 (0.1) 76 (0.0) 0.013 
bladder pain (%) 624 (0.0) 60 (0.0) 0.007 
cancer (%) 101845 (5.3) 24304 (8.3) 0.120 
CVD (%) 59740 (3.1) 10479 (3.6) 0.027 
dementia (%) 17949 (0.9) 1724 (0.6) 0.039 
diabetes (%) 381614 (19.7) 60293 (20.5) 0.021 
heart failure (%) 55489 (2.9) 11221 (3.8) 0.053 
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Table 1 (cont’d). Veterans Traits across long term opioid therapy exposure (LTOT) 
Variable No LTOT LTOT SMD 
ischemic heart disease (%) 211402 (10.9) 36956 (12.6) 0.052 
liver (%) 4072 (0.2) 1201 (0.4) 0.036 
liver - mild (%) 39903 (2.1) 9551 (3.3) 0.074 
pulmonary (%) 163187 (8.4) 34910 (11.9) 0.115 
PVD (%) 57623 (3.0) 12210 (4.2) 0.064 
renal (%) 66755 (3.4) 11575 (3.9) 0.026 
anxiety (%) 147381 (7.6) 28730 (9.8) 0.077 
bipolar disorder (%) 57515 (3.0) 10406 (3.5) 0.032 
concussion (%) 7319 (0.4) 1457 (0.5) 0.018 
depression (%) 306708 (15.8) 60691 (20.7) 0.125 
ptsd (%) 226542 (11.7) 38049 (13.0) 0.038 
schizophrenia (%) 34813 (1.8) 4465 (1.5) 0.022 
TBI (%) 11603 (0.6) 1888 (0.6) 0.006 
sleep disorder (%) 187562 (9.7) 31618 (10.8) 0.036 
subs. abuse - alcohol (%) 138944 (7.2) 24465 (8.3) 0.043 
subs. Abuse - opioid (%) 14526 (0.8) 3081 (1.1) 0.032 
subs. abuse - other (%) 78688 (4.1) 14020 (4.8) 0.035 
suicidal ideation (%) 18297 (0.9) 2846 (1.0) 0.003 





 THE EFFECT OF LONG TERM OPIOID THERAPY INITIATION ON THE 
PROBABILITY OF EMERGENCY DEPARTMENT UTILIZATION  
Introduction 
Long term opioid therapy (LTOT) for chronic pain has been under scrutiny over the past 
two decades. In the late 1990s, there was a push to screen, recognize, and treat chronic pain in 
response to perceived undertreatment in the US. By 2005, guidelines shifted to a focus on multi-
disciplinary pain care with a decreasing emphasis on as-needed pain analgesics. As of 2016, the 
Centers for Disease Control (CDC) released recommendations stating ‘non-opioid therapy 
should be preferred to opioid therapy for the treatment of chronic pain’. Furthermore, ‘Opioids 
were associated with increased risks, including opioid use disorder, overdose, and death, with 
dose-dependent effects’. The medical use of opioids increased substantially from 2000 to 2011, 
then plateaued in recent years68. At the same time, the rate of opioid related drug overdose 
deaths108 has doubled between 2000-2016 in the US69. In response to the public health crisis of 
increasing rates of opioid overdose deaths, there have been calls for reduction in long term 
opioid prescribing to help combat opioid overdose deaths.    
Despite well-documented decreases in opioid prescribing in the US, it remains unclear 
what effect these national decreases will have on the patients experiencing chronic pain. Some 
pain experts have expressed concern the pendulum of long term opioid therapy use has over-
corrected in recent years, potentially causing harm by stigmatizing providers prescribing LTOT 
and patients who may depend on LTOT for compassionate care70,109.  The Veteran’s Health 
Administration (VHA) system is an ideal setting to study the effect of LTOT on patient level 
outcomes. Compared with their civilian counterparts, the US Veteran population is at increased 
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risk of experiencing chronic pain. The VHA system has also been responsive to the national call 
for reductions in opioid prescribing; implementation of the Opioid Safety Initiative at the VHA 
has been associated with large reductions in opioid prescribing110. There is a paucity of evidence 
describing the population average risks of LTOT exposure among the patients reporting chronic 
pain. We aware of only one clinical trial evaluating the effect of opioid assisted-treatment 
compared with non-opioid assisted pain treatment9. Balancing the potential effects of the health 
care system level changes in LTOT on actual patient level outcomes is difficult due to the lack of 
epidemiologic evidence of the risks of LTOT in this population.  
To fill this knowledge gap, we sought to identify the association between exposure to 
prescribed long term opioid therapy among Veterans reporting incident chronic pain, and 
subsequent emergency department utilization.  We identified a national cohort of Veterans 
actively engaged in primary care at medical centers in the Veterans Health Administration and 
reporting incident chronic pain between 2009 and 2015. We then estimated the association 
between LTOT and any emergency department visit adjusted or balanced for observed patient 
characteristics using direct regression adjustment and propensity score analysis. We also 
evaluated time-varying facility prescribing preference as a potential instrument for LTOT for use 
in an instrumental variable analysis to estimate the the association between LTOT and any 
emergency department visit  
Methods 
Cohort  
In this retrospective cohort study, we sought to assess the association between LTOT 
exposure and subsequent ED utilization among US Veterans. We identified a cohort of Veterans 
receiving regular primary care at VHA medical centers and reporting incident chronic pain 
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between 2008-01-01 and 2015-01-01.  We first identified all Veterans engaged in active primary 
care at the start of each fiscal-year quarter. We defined ‘active primary care’ as any primary care 
visit in the two years prior to the start of each fiscal-year quarter. Accordingly, we identified all 
Veterans with an outpatient primary care visit in the VHA between 2006-01-01 and 2015-06-01. 
Amongst those Veterans, we limited the cohort to Veterans with no recorded date of death prior 
to 2008-01-01. Outpatient visits were classified as primary care by clinic stop code using the 
VHA electronic healthcare record. We identified the first quarter in which a Veteran reported 
chronic pain, and considered the first day of this quarter to be the Veteran’s baseline date. If a 
Veteran reported chronic pain in any of the quarters between 2006 and 2008, they were 
considered prevalent cases and excluded from the study (a two-year washout period). Veterans 
with missing values for gender, date of birth, race, or ethnicity were excluded from the study 
cohort. A small portion of Veterans were identified to have multiple values for race. These 
Veterans also had excessively higher observed utilization, leading to higher rates of all 
utilization-based variables and outcomes. These Veterans were excluded from the study, as the 
most likely explanation is data or Veteran identifier errors. Veterans were censored from the 
study at the time of death, or if more than two years had passed from the last primary care visit. 
Veterans without four full quarters of follow-up following baseline were excluded from the 
study. Veterans were linked to their home primary care facility as described below. Veterans 
whose home primary care facility was a medical center were included in the study.  
Since we intended to use up to one prior year of facility prescribing data in the 
instrumental variable analysis, the ‘at-risk cohort’ was restricted to Veterans with a baseline date 
of 2009-01-01 to 2015-01-01. Veterans with a baseline date in 2008 were only used in the 
instrumental variable analysis to identify past prescribing behavior.   
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Identifying Chronic Pain 
We sought to define Veterans reporting chronic pain based on either of two criteria: (1) 
Persistently elevated Veteran reported pain scores, or (2) patterns of diagnostic codes related to 
chronic pain. Chronic pain is commonly defined as pain lasting longer than 3 months71. The 
VHA regularly captures pain scores during clinical encounters using the numeric pain rating 
scale, where 0 represents no pain, and 10 represents the worst possible pain. Following prior 
studies7,111, we defined pain scores of 1-3 as mild pain, pain scores of 4-6 as moderate pain, and 
pain scores of 7-10 as severe pain. In order to identify persistent pain, we identified Veterans 
reporting at least three pain scores of 4 or higher (moderate to severe pain), with at least 30 days 
between the pain scores, but no more than 365 days between the first and last pain score. 
Veterans meeting this criterion were considered as reporting persistent moderate-severe pain. We 
repeated this algorithm for pain scores of 7 or higher to identify Veterans reporting persistent 
severe pain. Veterans meeting these criteria were considered to be reporting persistent pain as of 
the date of the first pain score.  
In addition to using pain scores to identify Veterans reporting chronic pain, we used 
diagnosis codes to identify Veterans with conditions likely to be associated with chronic pain. 
Conditions were identified based on prior work2,25 and included joint pain, limb pain, back and 
neck pain, osteoarthritis and spondylosis, abdominal pain, headache and migraine, arthropathy, 
rheumatoid arthritis and inflammatory polyneuropathies, neuropathies, fibromyalgia, multiple 
sclerosis, painful bladder syndrome, genitourinary pain, multiple dystrophy, spinal cord injury, 
central pain syndrome, post-operative pain, and cancer pain. Veterans were required to have at 
least two diagnosis codes (inpatient or outpatient) with at least 90 days but no more than 365 
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days between the diagnosis code dates. Veterans meeting this condition were considered to be 
experiencing a chronic pain related condition as of the date of the first diagnosis code.  
Identifying Veteran Comorbidities and Demographics  
We identified chronic comorbidities using international classification of disease (ICD) 
diagnostic codes, including congestive heart failure, uncomplicated diabetes, complicated 
diabetes, lymphoma, metastatic cancer, obesity, chronic pulmonary disease, peripheral vascular 
disorders, renal failure, solid tumor without metastasis, valvular disease, and liver disease. We 
also identified suicidal ideation, suicide attempt or self-injury, organic or non-organic sleep 
disorders, post-traumatic stress disorder, traumatic brain injury, concussion, depression, anxiety 
disorder, schizophrenia and other psychotic disorders, bipolar or manic disorder, opioid use 
disorder, alcohol related disorders, and other substance abuse disorder. ICD9/10 codes for these 
conditions were grouped using the Agency for Healthcare Research and Quality (AHRQ) 
Clinical Classifications Software (CCS) combined with expert review of codes. Following prior 
VHA studies6,111, we required one inpatient or two outpatient diagnoses on separate days 
between the prior 4 quarters and the quarter after the baseline date.  
Veteran demographics including age, race, ethnicity, gender, and urban/rural status were 
identified from the VHA central data warehouse. Age was calculated as of the first day of each 
quarter, and categorized into groups of 18-35, 35-45, 45-55, 55-65, 65-75, and 75+. Race and 
ethnicity were categorized into a single variable as white non-Hispanic, black non-Hispanic, 
Hispanic, and other.  
Identifying Home Facility 
Each Veteran was assigned to a home facility based on patterns of primary care visits in 
the 4 quarters preceding baseline and the baseline quarter. We extracted all outpatient visits 
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occurring in primary care clinics as indicated by clinic stop codes. We aggregated these visits by 
facility identifier and took the most frequently occurring facility as the ‘home facility’.   
Exposure: Long Term Opioid Therapy 
We assessed if each Veteran was exposed to long term opioid therapy in the baseline 
quarter where incident chronic pain was reported, or the quarter immediately following baseline. 
LTOT was defined as 90 or more days’ supply of opioids within any 365-day period. Opioids 
included butorphanol, codeine, fentanyl, hydrocodone, hydromorphone, levorphanol, 
meperidine, morphine, oxycodone, oxymorphone, pentazocine, propoxyphene, tapentadol, or 
tramadol. A veteran was considered exposed to long term opioid therapy as of the first day of the 
first prescription meeting the criteria above. 
Outcome 
The outcome in all models was a binary variable indicating if there was any emergency 
department (ED) utilization in the second through fourth quarters following baseline for each 
Veteran. ED utilization was identified using VHA electronic medical records, based on clinical 
stop codes for emergency department and urgent care (clinic stop codes 130, 131, 297).  
LTOT and any ED Visit: Direct Regression Adjustment 
We first compared the unadjusted probability of any ED visit between Veterans exposed 
to LTOT versus those unexposed by fitting a logistic regression with ED visit as the dependent 
variable, and prior LTOT exposure as the independent variable.  In order to adjust for potential 
differences among exposed and unexposed Veterans, we also fit an adjusted logistic regression 
model by including all covariates from table 1 with a Standardized Mean Difference (SMD) >= 
0.1 as independent variables (back/neck pain, other pain, gout, age, race, and depression).  
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Propensity Score Analysis 
To estimate the average treatment effect (ATE) of LTOT on any emergency department 
utilization adjusting for measured confounders, we used propensity score analysis with inverse 
probability of treatment weighting to adjust for measured confounders82,83.  We first estimated 
the probability of LTOT exposure using a logistic regression with Veteran demographics, 
chronic comorbidities, and chronic pain conditions as independent variables. We examined the 
distribution of the LTOT probabilities stratified by LTOT status to check for valid 
counterfactuals, i.e. that there was complete overlap in the distribution of propensity scores for 
both exposed and unexposed Veterans. We then weighted each observation according to the 
inverse probability of treatment and implemented a logistic regression with LTOT as the single 
independent variable, and ED utilization as the dependent variable. The primary analysis used 
the full cohort. When using inverse probability of treatment weighting, observations with large 
weights may unduly influence results84,85. As a sensitivity test, we removed Veterans with an 
inverse probability of treatment weight greater than 20 and repeated the analysis, but the results 
did not qualitatively change.   
Instrumental Variable Analysis 
An instrumental variable (IV) analysis can estimate the causal effect of an exposure on an 
outcome in the presence of unmeasured confounding if a valid instrument can be identified. An 
instrument is a variable that predicts exposure status, but does not affect the outcome except 
through the exposure. More formally, the instrument must meet three conditions86: (1) the 
instrument is strongly associated with the exposure (relevance), (2) the instrument has no causal 
effect on the outcome except through the exposure (the exclusion restriction), and (3) the 
instrument is not associated with unmeasured confounders of the outcome (exchangeability). 
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Under these three conditions, an IV analysis can identify an upper and lower bound of the 
average treatment effect. To identify a point estimate, we must also assume effect homogeneity, 
which is often unreasonable in practice. If we can assume monotonicity, we can estimate the 
local average treatment effect (LATE), which is the treatment effect among the compliers112. The 
compliers are the subset of Veterans whose exposure status is influenced by the instrument. 
Veterans who are never exposed despite the instrument value, or always exposed despite the 
instrument are termed never-takers and always-takers. If an instrument is only weakly to 
moderately associated with the exposure, the resulting estimate of treatment effect may be biased 
as the conditions listed above are violated88. Even if the instrument is strongly associated with 
exposure, violations of the exchangeability assumption can cause bias. To evaluate 
exchangeability, we constructed bias component plots for both the exposure and the instrument 
to visually evaluate possible exchangeability violations89,113.  
A potential instrument used in prior studies is provider or facility prescribing 
preference91–93,95,106. This measures the likelihood that patients will be prescribed LTOT when 
treated at a given facility. We used the method developed and described in chapter V to identify 
time-varying facility prescribing preference. We identified time-varying facility prescribing 
preference using a two-stage approach adjusting for Veteran characteristics and implementing 
shrinkage to stabilize small cluster estimates. We used 4 previous quarters of data to generate the 
estimates and chose an intermediate level of shrinkage with alpha == 0 and lambda == 10 for the 
shrinkage parameters.  
To assess the validity of the instrument due to potential unobserved confounders, we 
constructed bias component plots89,113 . Bias component plots show ‘the covariate balance by 
treatment alongside the scaled covariate balance by the proposed instrument’. The scaling factor 
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appropriately accounts for the strength of the instrument. We additionally follow the suggestion 
of Davies 2017 and add confidence intervals to this plot.  
Although various forms of implementing an instrumental variable analysis in the context 
of a binary treatment and outcome have been proposed, recent simulation studies have identified 
the two-stage least squares (2SLS) approach as the optimal approach114. In 2SLS, the first stage 
model is a linear model with treatment (LTOT) as the outcome, and the instrument with any 
adjustment variables as the predictors. In the second stage, we predict exposure using the first 
stage model, then replace the Veteran level exposure variable with this predicted exposure.  
We implemented the two-stage least squares IV analysis. In the first stage, we fit a linear 
model with LTOT as the dependent variable, and home facility, Veteran chronic comorbidities, 
demographics, and chronic pain conditions as the independent variables. We evaluated the 
strength of the instrument using partial r-squared, F-statistic, and the risk difference associated 
with the instrument. We constructed bias component plots for both LTOT exposure and the 
instrument.  
Software 
We used Microsoft Server SQL for initial data management. We also used R Version 
3.4.3 for data analysis, management, and visualization. Elastic-net generalized linear models 
were fit with the GLMNet package in R73.   
Results 
Study Population 
We identified 1,030,263 Veterans receiving regular primary care at VHA medical centers 
reporting incident chronic pain between 2009-01-01 and 2015-01-01 eligible for the study 
(Figure 1). Table 1 summarizes demographic traits of the study population, stratified by LTOT 
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exposure. The population demographics were consistent with prior studies of US Veterans, with 
~90% of the study cohort male gender and ~70% white race. The most common pain conditions 
were back/neck pain, joint pain, and osteoarthritis, all with prevalence above 10%. The most 
common chronic disease comorbidities were diabetes, ischemic heart disease, and chronic 
pulmonary disorder. Depression, post-traumatic stress disorder, and sleep disorder were the most 
common mental health comorbidities.  
Exposure to LTOT 
The primary exposure of interest, exposure to long term opioid therapy in the first two 
quarters of follow-up, was somewhat common with 12.7% of the population exposed. Some 
covariates were substantially imbalanced across exposure state, as evidenced by the standardized 
mean difference values above 0.1. White race and age 45-65 were associated with a higher rate 
of LTOT exposure. Among pain conditions, back/neck pain and other pain were associated with 
higher rates of LTOT, while gout was associated with lower rates of LTOT. Among chronic 
illnesses, cancer and pulmonary disorder were associated with higher rates of LTOT exposure. 
Among mental health comorbidities, depression was associated with higher rates of LTOT.  
Emergency Department Utilization 
The outcome of any emergency department utilization was relatively common, with 24% 
(n=247,257) of the study population utilizing the ED.  
Unadjusted and Adjusted Regression 
Table 2 summarizes the odds ratios from the different analytic approaches used to 
estimate the average treatment effect of exposure to LTOT on the subsequent probability of ED 
utilization. In unadjusted modeling using a logistic regression, the odds of any ED utilization was 
1.277 (95% CI: 1.268-1.285) times higher among Veterans exposed to LTOT compared to 
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Veterans not exposed to LTOT. After adjusting for variables with an SMD > 0.1 (age category, 
race, back/neck pain, joint pain, other pain, cancer, pulmonary disorder, and depression), the 
association between LTOT and the subsequent probability of ED utilization was qualitatively 
identical, with an odds ratio of 1.281 (95% CI: 1.272-1.29).  
Propensity Score Analysis 
We calculated the probability of LTOT exposure conditional on variables with an SMD > 
0.1 (age category, race, back/neck pain, joint pain, other pain, cancer, pulmonary disorder, and 
depression), then summarized the distribution of scores in figure 2. There was adequate overlap 
of the propensity scores as assessed by visual examination (figure 2) and by identifying at least 
one Veteran in each of the exposed and unexposed groups having the minimum and maximum 
propensity score.  
Using the IPTW propensity score approach, we found the odds of any ED utilization was 
1.051 (95% CI: 1.048-1.055) times higher among Veterans exposed to LTOT compared to 
Veterans not exposed to LTOT.  
Instrumental Variable Analysis 
We considered time varying facility prescribing preference as a potential instrument to 
estimate the association between LTOT exposure and subsequent ED utilization, but the 
potential instrument did not satisfy all the conditions for a valid IV. The instrument exhibited 
monotonicity, with a monotonic and roughly linear increase in the probability of LTOT exposure 
across the quintiles of the instrument. After implementing the first stage linear model, the 
instrument was deemed sufficiently strong; the F-statistic was 122.25, the additive difference in 
risk between for an increase in quintile of prescribing preference (the instrument) was 0.127 and 
the corresponding multiplicative ratio was 2.816. We next examined bias plots for demographics 
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(figure 3), mental health conditions (figure 4), and pain related conditions (figure 5). The bias 
plots showed that the instrument did not provide improved balance of the measured covariates. If 
the instrument is also associated with unobserved confounders, it is possible the analysis using 
the instrument would be more biased than the propensity score or direct regression analysis. 
Since the validity of the instrument was questionable, we did not implement the instrumental 
variable analysis.  
Discussion 
In this observational cohort study, we sought to estimate the average treatment effect of 
LTOT on subsequent ED utilization. We found a moderately sized positive association (LTOT is 
a slight risk factor for risk of ED utilization) using the direct regression adjustment method, and 
only a small positive association using propensity scores with weighting. Despite identifying a 
strong predictor of exposure (facility prescribing preference), we did not implement the 
instrumental variable analysis as there were systemic differences in patient traits across levels of 
the instrument.  
The history of chronic pain and opioid prescribing in the US has been a pendulum. In the 
late 1990’s, there were concerns about the undertreatment of pain59, with guidelines encouraging 
physicians to recognize and treat pain, possibly with opioids. By the mid 2000’s, updated 
guidelines62 called for a reduction in as-needed analgesic medications such as opioids, and an 
increase in multi-modal pain care. As of 2016, guidelines for opioid prescribing for chronic pain 
recommend against opioid therapy, including strong wording of adverse opioid therapy effects: 
‘Opioids were associated with increased risks, including opioid use disorder, overdose, and 
death, with dose-dependent effects’. In the current environment, opioid therapy for chronic pain 
has been stigmatized for both providers and patients. The increase in prescription opioids has 
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often been mentioned in the context of the current opioid overdose epidemic. However, most 
opioid overdoses are due to illicit opioids70 rather than prescription opioids. Notably, in this 
study of over one million Veterans, we find conflicting evidence of an association between 
LTOT and ED utilization among Veterans reporting incident chronic pain.  
These findings provide a valuable additional data point for the ongoing discussion of the 
role of opioid prescribing in the current opioid overdose public health crisis. Experts have 
questioned the efficacy of LTOT in treating patients with chronic pain, and recent studies have 
supported the hypothesis that LTOT is not superior to other treatments for chronic pain9. 
However, strong evidence of the harms of appropriate long term opioid exposure has been absent 
from the literature -- a systematic review cited by recent guidelines identifies only limited 
observational evidence for increased risk of harms associated with LTOT66. An observational 
study of Medicaid beneficiaries in Tennessee found a small but statistically significant 
relationship between exposure to long acting opioid medication and mortality67.  This study 
provides an important data point on the potential harmful effects of LTOT for patients legally 
prescribed the drugs. We find a small to moderate harmful effect of LTOT; this may be 
explained by a true risk of LTOT initiation, or by treatment indication bias due to residual 
unobserved confounding.   
This study highlights the challenge of using observational data to make causal inference 
on treatment effects. Observational study design generally seeks to use variation in exposure 
along with observed outcomes to estimate the causal risk association between exposures and 
outcomes. To identify a causal effect, the variation in exposure cannot be endogenous. Direct 
regression methods and propensity score methods assume ‘no unmeasured confounding’, 
conditional on observed covariates. However, the existence of variation in exposure after 
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adjusting for all relevant covariates challenges the underlying assumption of no unmeasured 
confounding – if all confounders have been observed, why is there any residual variation in 
treatment exposure? One possible explanation is treatment indication bias; patients who received 
LTOT are less healthy than those who did not receive LTOT, but that difference is not measured 
in the observed dataset. Unobserved confounding can bias estimates of the average treatment 
effect when using direct regression adjustment or propensity score modeling.  
Another possible source of variation in patient exposure to LTOT is at the system level. 
Different medical providers may be more or less likely to prescribe LTOT for the same 
theoretical patient, leading to variation in LTOT exposure among otherwise similar patients. This 
is a promising source of variation for causal inference in observational data. In prior work 91–
93,95,106, this has been conceptualized as physician/facility prescribing preference using an 
instrumental variable approach. However, finding a valid instrument remains a challenge. In the 
current study, we showed that prescribing preference strongly predicted subsequent exposure. 
Despite this, the balance of covariates was not improved across levels of the instrument, 
indicating there may be systematic differences in the high and low prescribing hospitals which 
could bias the results. Further studies should examine the phenomena of facility level LTOT 
variation in depth, which may lead to construction of a valid instrument.  
In the direct regression adjustment approach, we found a moderate effect size with an 
odd’s ratio of 1.28. However, using a propensity score with IPTW, we found a much smaller but 
statistically significant association between LTOT and subsequent ED utilization. These 
estimates were qualitatively similar (small and significant), but different in absolute magnitude. 
Prior work has identified that results from propensity score methods and direct regression 
adjustment methods may not coincide for a variety of reasons72, although the magnitude of the 
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difference her is larger than usual. The direct logistic regression in this study is estimating the 
subject-specific effect (also called the conditional effect), or the expected difference in 
probability of any ED utilization if an individual patient were moved from treatment to no 
treatment. Alternatively, the marginal treatment effect is the population average expected 
difference in probability of any ED utilization if the population were moved from treatment to no 
treatment (also called the marginal effect). The propensity score method used here estimates the 
marginal treatment effect, which we expect to be attenuated to the null.  
A primary strength of this study is the large study-specific dataset of more than one 
million veterans spanning multiple years, representing comprehensive coverage of the US 
Veteran population receiving active primary care and reporting incident chronic pain. The study 
inclusion criteria (actively receiving primary care and reporting incident chronic pain) allows 
generalization of the results directly to the population and question of interest – if a Veteran 
reports incident chronic pain, what are the risks associated with exposure to LTOT?  Another 
strength is use of several complementary statistical methods, allowing examination of sensitivity 
of results to analysis methods.  The study also has some limitations that are typical of any 
observational study leveraging data collected for clinical purposes. While use of a national 
electronic health record allows construction of a comprehensive cohort, the data is still 
observational in nature. Unobserved confounding may exist and may bias estimates from the 
analyses. The data used to construct all measures was derived from clinical datasets; diagnoses 
and encounters may have been miscoded. We were unable to capture utilization of care outside 
of the VHA system, and some Veterans may be dual users of VHA services and external care. To 
limit the impact of this issue, the study inclusion criteria identified Veterans actively using VHA 
primary care services.  
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In conclusion, using a contemporary cohort of over one million US Veterans reporting 
incident chronic pain we find a positive and significant association between LTOT exposure and 
the probability of subsequent emergency department utilization. The increased risk of a negative 
health outcome associated with LTOT prescribing is potentially small in a large population of 
Veterans reporting incident chronic pain. Changes in health policy focused purely on reduction 
of access to prescribed LTOT among the broad population of chronic pain patients may not have 

























Table 1. Population Demographics and comorbidities stratified by LTOT 
Variable No LTOT LTOT Overall SMD 
n 899218 131045 1030263  





race (%)    0.137 
   black 198000 (22.0) 23735 (18.1) 
221735 
(21.5)  
   Hispanic 67910 (7.6) 7851 (6.0) 75761 (7.4)  
   other 22900 (2.5) 2446 (1.9) 25346 (2.5)  
   white 610408 (67.9) 97013 (74.0) 
707421 
(68.7)  
age (%)    0.209 
   [18,35) 146617 (16.3) 17693 (13.5) 
164310 
(15.9)  
   [35,45) 100292 (11.2) 14037 (10.7) 
114329 
(11.1)  
   [45,55) 149287 (16.6) 27437 (20.9) 
176724 
(17.2)  
   [55,65) 243658 (27.1) 42632 (32.5) 
286290 
(27.8)  
   [65,75) 143378 (15.9) 17205 (13.1) 
160583 
(15.6)  
   [75,120] 115986 (12.9) 12041 (9.2) 
128027 
(12.4)  
Joint disorder (%) 215622 (24.0) 29155 (22.2) 
244777 
(23.8) 0.041 
Osteoarthritis (%) 126269 (14.0) 18498 (14.1) 
144767 
(14.1) 0.002 
back/neck pain (%) 248821 (27.7) 54392 (41.5) 
303213 
(29.4) 0.294 
abdominal pain (%) 18014 (2.0) 2182 (1.7) 20196 (2.0) 0.025 
arthropathy (%) 16796 (1.9) 2647 (2.0) 19443 (1.9) 0.011 
other pain (%) 7958 (0.9) 4733 (3.6) 12691 (1.2) 0.185 
gout (%) 38282 (4.3) 2523 (1.9) 40805 (4.0) 0.135 
limb pain (%) 20583 (2.3) 2347 (1.8) 22930 (2.2) 0.035 
Neuropathy (%) 47600 (5.3) 4953 (3.8) 52553 (5.1) 0.073 
headache/migraine (%) 58091 (6.5) 6795 (5.2) 64886 (6.3) 0.054 
rheum. arthritis (%) 5725 (0.6) 988 (0.8) 6713 (0.7) 0.014 
fibromyalgia (%) 4876 (0.5) 1088 (0.8) 5964 (0.6) 0.035 
MS (%) 2396 (0.3) 220 (0.2) 2616 (0.3) 0.021 
spinal cord injury (%) 746 (0.1) 221 (0.2) 967 (0.1) 0.024 
multiple dystrophy (%) 227 (0.0) 19 (0.0) 246 (0.0) 0.008 
genitourinary pain (%) 551 (0.1) 43 (0.0) 594 (0.1) 0.013 
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Table 1 (cont’d). Population Demographics and comorbidities stratified by LTOT 
Variable No LTOT LTOT Overall SMD 
bladder pain (%) 247 (0.0) 24 (0.0) 271 (0.0) 0.006 
cancer (%) 49341 (5.5) 12108 (9.2) 61449 (6.0) 0.144 
CVD (%) 29209 (3.2) 4827 (3.7) 34036 (3.3) 0.024 
dementia (%) 10102 (1.1) 912 (0.7) 11014 (1.1) 0.045 
diabetes (%) 169600 (18.9) 26457 (20.2) 
196057 
(19.0) 0.034 
heart failure (%) 27607 (3.1) 5310 (4.1) 32917 (3.2) 0.053 
ischemic heart disease (%) 92311 (10.3) 16154 (12.3) 
108465 
(10.5) 0.065 
liver (%) 2234 (0.2) 616 (0.5) 2850 (0.3) 0.037 
liver - mild (%) 21547 (2.4) 4844 (3.7) 26391 (2.6) 0.076 
pulmonary (%) 76098 (8.5) 15758 (12.0) 91856 (8.9) 0.118 
PVD (%) 26767 (3.0) 5673 (4.3) 32440 (3.1) 0.072 
renal (%) 33829 (3.8) 5697 (4.3) 39526 (3.8) 0.030 
anxiety (%) 74554 (8.3) 13448 (10.3) 88002 (8.5) 0.068 
bipolar disorder (%) 29877 (3.3) 4952 (3.8) 34829 (3.4) 0.025 
concussion (%) 4381 (0.5) 863 (0.7) 5244 (0.5) 0.023 
depression (%) 150168 (16.7) 27556 (21.0) 
177724 
(17.3) 0.111 
ptsd (%) 111401 (12.4) 17397 (13.3) 
128798 
(12.5) 0.027 
schizophrenia (%) 18814 (2.1) 2139 (1.6) 20953 (2.0) 0.034 
TBI (%) 6607 (0.7) 999 (0.8) 7606 (0.7) 0.003 
sleep disorder (%) 95313 (10.6) 15108 (11.5) 
110421 
(10.7) 0.030 
subs. abuse - alcohol (%) 74493 (8.3) 12134 (9.3) 86627 (8.4) 0.034 
subs. abuse - opioid (%) 9142 (1.0) 1670 (1.3) 10812 (1.0) 0.024 
subs. abuse - other (%) 46426 (5.2) 7458 (5.7) 53884 (5.2) 0.023 
suicidal ideation (%) 11605 (1.3) 1648 (1.3) 13253 (1.3) 0.003 





Table 2. Summary of Odds Ratios of LTOT on Any ED Utilization using different modeling 
techniques.  
  Odds Ratio 
Crude 1.277 (95% CI: 1.268-1.285) 
Model 1 * 1.281 (95% CI: 1.272-1.29) 
Model 2 + 1.051 (95% CI: 1.048-1.055) 
Model 3 ^ 1.05 (95% CI: 1.047-1.054) 
* Model 1 was a logistic regression, adjusted for any variables from table 1 with SMD > 0.1 
+ Model 2 was the propensity score approach, with the probability of treatment model adjusted for any variables 
from table 1 with SMD > 0.1 
^ Model 3 was the propensity score approach, with the probability of treatment model adjusted for any variables 
from table 1 with SMD > 0.1. Weights greater than 20 were trimmed.  
98 
 
CHAPTER VII  
SUMMARY AND FUTURE DIRECTION 
This dissertation work is a direct response to the Institute of Medicine (IOM)1  
recommendations that ‘federal agencies improve the collection and reporting of data on pain’.  
We constructed a comprehensive national cohort of ~10 million Veterans actively engaged in 
VHA care spanning 8 years. In the first aim, we report the prevalence of chronic pain across time 
and demographics using this comprehensive cohort and contextualize these results with trends in 
the prevalence of other common chronic conditions and mental health comorbidities.  In the 
second aim, we develop a novel ensemble method with variable shrinkage and patient mix 
adjustments to identify high and low prescribing facilities in the context of longitudinal data. 
This method is potentially useful for identifying facility prescribing preference for use as an 
instrument. We demonstrate allowing a variable degree of shrinkage and using supervised 
machine learning techniques to optimize the degree of shrinkage identifies stronger instruments. 
In the third aim, we use a cohort of Veterans reporting incident chronic pain to explore the 
association between initiation of long term opioid therapy (LTOT) and subsequent emergency 
department utilization. Using both direct regression adjustment techniques and propensity score 
techniques, we find a statistically significant but potentially small positive association between 
LTOT exposure and ED utilization. Between 2008 and 2015 there was a decrease in the overall 
number of Veterans in the US. The US economy exhibited steady growth and unemployment 
generally decreased. Despite this, we found the population of Veterans seeking care at the VHA 
has increased substantially --- a 25% increase in the number of Veterans engaged in active 
primary care. These Veterans are increasingly reporting chronic pain related conditions and 
mental health comorbidities, while traditional comorbidities are stable in prevalence. At the same 
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time, the VHA had attempted to increase the use of community care to meet demand. Veterans 
with chronic pain and mental health comorbidities are challenging to care for; it is unclear if the 
private sector is equipped to give high quality care to this segment of Veterans who are 
increasingly prevalent. Future work should focus on evaluating the quality of care available in 
the community for Veterans with these complex conditions.  
A strength of this work is the combination of using both pain scores and diagnostic 
history to assess evidence of chronic pain among a full cohort of Veterans in primary care. Prior 
work identifying the prevalence and incidence of chronic pain has generally not included both 
constructs (pain scores and diagnoses). Future work with this cohort should explore the 
interaction between longitudinal pain scores and different pain conditions. A particularly 
interesting subset of Veterans is those reporting chronic pain through multiple pain scores, but 
without a specific diagnosis related to chronic pain. These Veterans may exhibit different 
utilization patterns and be at a higher risk for negative health outcomes. Future work should 
identify the utilization and outcome patterns of this sub-group.  
In the third aim of this work, we found that Veterans reporting incident chronic pain who 
were exposed to long term opioid therapy were at a statistically significant but potentially mild 
increased risk of emergency department utilization. This is a valuable quantitative contribution to 
the ongoing debate of the role of legal LTOT therapy in the opioid overdose public health crisis. 
There was a large increase in the number of opioids prescribed in the 2000’s, which coincided 
with an increase in drug overdose fatalities in the US. This has led to speculation that the 
prescription of opioids drove the drug overdose epidemic and exposure to LTOT has a high risk 
of negative health outcomes. This is stigmatizing for both patients seeking pain care who may 
consider opioid therapy, and physicians prescribing opioids. This work does not necessarily 
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support this commonly held belief that there is a direct association between LTOT and negative 
health outcomes among Veterans reporting chronic pain. A possible explanation for this 
discrepancy in perceived risks is the source population for the study. Chronic pain is common in 
Veterans, and the population of Veterans seeking care and reporting chronic pain is not generally 
the same population of Veterans at high risk for illicit substance abuse. Conflating these 
populations may be inappropriately stigmatizing to Veterans reporting chronic pain who need 
compassionate care. It is important to note that recent work has shown that opioid assisted pain 
therapy is not more effective than non-opioid assisted pain therapy9, and therefore efficacy of 
LTOT as a therapeutic agent in chronic pain should be carefully assessed for each patient. Future 
research should focus on how pain care has changed in the VHA health care system beyond 
opioids and assess what impact these changes have had on patient level outcomes.  
In the second aim of this work, we present a novel approach to identifying high and low 
prescribing facilities. The ensemble method can use non-parametric machine learning 
approaches to case mix adjustment and flexibly implement different degrees of shrinkage.  This 
is an important contribution to the field of statistical profiling; the tradeoff between using overly 
sensitive methods with no shrinkage and potentially overly insensitive methods with shrinkage 
(such as frequentist random effects models) has been documented in multiple studies102,103,115, 
but few solutions have been offered. Directly parameterizing the degree of shrinkage, then 
applying a machine learning approach to optimize the degree of shrinkage is a novel integration 
of machine learning and traditional statistical inference. Furthermore, the proposed ensemble is 
efficient and therefore ideal for larger datasets. By using the elastic-net regularization framework 
to achieve shrinkage, we could fit this model on data with millions of rows. Future work should 
contrast this method with Bayesian and frequentist shrinkage estimators. 
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This work also highlights the promise and challenges of using ‘big medical data’ (that are 
still observational) to make causal inference on the relationship between exposures and 
outcomes. The traditional perspective on the hierarchy of evidence-based medicine considers 
randomized controlled trials to be superior to observational studies116,117. Observational data 
suffers from potential bias due to unmeasured confounding, especially by indication. Clinical 
trials use randomization to overcome unmeasured confounders but can suffer from 
generalizability --- patients who participate in clinical trials often do not resemble the general 
population of patients a provider cares for. In recent years, there has been an explosion in the 
availability of big healthcare datasets coupled with excitement about ‘machine learning’ and 
‘artificial intelligence’ techniques in medicine118. While the rapidly evolving field of machine 
learning has proven useful for improving predictive modeling, this should not be confused with 
improvements in identifying causality. Big observational datasets are still observational in 
nature--the fundamental issue of unmeasured confounding is not solved simply by observing 
more data.  
One promising technique for causal inference in big data is instrumental variable analysis 
(IVA). In the third aim of this work, we implemented an IVA to use variation in care (LTOT 
prescribing patterns) at the facility level to identify the effect of long term opioid therapy on 
emergency department utilization. We considered facility level prescribing preference to be the 
instrument. This approach holds high conceptual appeal; similar Veterans will receive different 
care depending on which facility they visit. Can we contrast their average outcomes to identify 
the causal effect of the difference in care? We found the instrument was strong--- facility 
behavior over time was a powerful predictor of LTOT exposure. However, Veterans at those 
facilities were different on key variables, thus the instrument was potentially invalid. The 
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variation in LTOT exposure at the facility level should be further explored and understood. It is 
possible that a valid instrument leveraging facility level variation in LTOT among Veterans can 
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